Insight into the Interaction Between the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Adipocyte Fatty Acid-Binding Protein (A-FABP) by Wang, Qian
City University of New York (CUNY) 
CUNY Academic Works 
All Dissertations, Theses, and Capstone 
Projects Dissertations, Theses, and Capstone Projects 
9-2017 
Insight into the Interaction Between the Peroxisome Proliferator-
Activated Receptor Gamma (PPARγ) and Adipocyte Fatty Acid-
Binding Protein (A-FABP) 
Qian Wang 
The Graduate Center, City University of New York 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/gc_etds/2381 
Discover additional works at: https://academicworks.cuny.edu 









INSIGHT INTO THE INTERACTION BETWEEN THE PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR𝛾) AND 














A dissertation submitted to the Graduate Faculty in Biochemistry 
 in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy  





























© 2017  
QIAN WANG 
All Rights Reserved  
iii 
 
INSIGHT INTO THE INTERACTION BETWEEN THE PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR𝛾) AND 




This manuscript has been read and accepted for the Graduate Faculty in 




Dr. Ruth E. Stark 
 
 
__________________________                   _________________________________ 
Date                                                               Chair of Examining Committee 
 
  
                                           
Dr. Richard S. Magliozzo 
 
 
____________________________             ___________________________________ 







Dr. Ranajeet Ghose, City College of New York 
Dr. Sébastien Poget, College of Staten Island 
Dr. Judith Storch, Rutgers University 
Dr. Cédric Bernard, City College of New York 
 






Insight into the interaction between the peroxisome proliferator-activated receptor gamma 




Advisor: Dr. Ruth E. Stark 
 
The Adipocyte Fatty Acid-Binding Protein (AFABP) is mainly expressed in fat cells. It can bind 
fatty acids and other lipophilic substances such as eicosanoids and retinoids. The peroxisome 
proliferator-activated receptor γ (PPARγ) is a nuclear receptor protein that requires ligand binding 
to regulate the specific gene transcription. PPARγ is expressed at extremely high levels in adipose 
tissue, macrophages, and the large intestine, where it controls lipid adipogenesis and energy 
conversion. Moreover, it has been found that AFABP and PPARγ can form a complex in vivo. It 
is proposed that AFABP carries the ligand and enters into the nucleus where it transfers the ligand 
to PPARγ by binding and macromolecular interaction. 
The goal of this project is to study the interaction between these two proteins in vitro, including 
their binding affinity, the location of the binding interface on the AFABP protein, and the 
dependence of these phenomena on specific ligands. New protocols were developed to obtain pure 
monomeric AFABP protein in a delipidated state.  The formation of a disulfide-linked dimer 
connected through an N-terminal cysteine was demonstrated and minimized by the exclusion of 
oxygen, though it is not known whether this dimer exists under physiological conditions. A 
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corresponding protocol was developed to isolate delipidated PPARγ and to optimize conditions 
for the acquisition of its high-resolution NMR spectra. 
Making sequence-specific backbone NH assignments and exploiting the local changes in the 
chemical environment that accompany interactions between the AFABP and PPARγ proteins, 
TROSY-HSQC NMR was used to determine which AFABP amino acid residues are located at 
their interface by investigating the perturbation of backbone NH NMR chemical shifts. The 
perturbed residues are located primarily in the portal region; weak binding between AFABP and 
PPARγ (Kd ~ 500 𝜇M) is estimated from chemical shift changes during titration. Fluorescence 
competition assays also provide insight on protein-ligand dissociation constants and show that the 
ligand prefers to bind AFABP rather than PPARγ. Nonetheless, titration of PPARγ with holo-
AFABP demonstrates the partial transfer of the ligand from AFABP to PPARγ, which could be 
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This introduction will begin with previously published studies of long-chain fatty acids (LCFA). 
By choosing several common and essential fatty acids, their structure and function will be 
summarized as well as their closely related lipid metabolism and human health implications. Prior 
studies have offered clues that LCFAs coordinate and regulate lipid metabolism through contacts 
and interactions with a variety of membranous, cytosolic and nuclear receptors. Two groups of 
these interaction candidates, fatty acid-binding proteins (FABPs) and peroxisome proliferator-
activated receptors (PPARs), will be highlighted in this Introduction. The discovery and 
importance of these two protein families in biological and biomedical areas will be described, 
especially the signaling pathways and regulation of correlated gene transcription and downstream 
lipid metabolism phenomena. Since the PPARs are activated or inhibited by binding various 
ligands, this introduction will present previous studies of their structures and how ligands are 
thought to mediate their regulation of gene transcription. According to the literature in recent 
decades, PPARs have been shown to interact, bind and cooperate with many other proteins, 
including several members of the FABP family. The FABPs carry the lipids and transfer them in 
both the cytosol and nucleus. Thus it is interesting to identify how these two lipid-binding proteins 
interact with each other, with a view toward understanding lipid metabolism and related human 




1.2. What are LCFA’s? 
The long-chain fatty acids (LCFA) comprise a large family of carboxylic acids connected to a long 
aliphatic chain, which typically contains 14-28 aliphatic carbon segments that are either saturated 
or unsaturated (Figure 1) in nature. In the saturated subgroup, all of the carbon atoms are connected 
by single bonds (-C-C-) without any double bonds (-C=C-). The most common examples found in 
living organisms are palmitic acid (16:0) and stearic acid (18:0), which possess 16 and 18 carbons, 
respectively. By contrast, the polyunsaturated fatty acids contain one or more carbon-carbon 
double bonds in the constituent aliphatic carbon chains. According to the position of the final 
carbon-carbon double bond, the polyunsaturated fatty acids are designated as ω-3, ω-6, ω-7, ω-9 
and so on. Some of the essential unsaturated fatty acids are common in nature, e.g., 𝛼-linolenic 
acid (ALA), which is 18:3 (n-3), and oleic acid (OLA), which is 18:1 (cis-9). The well-known 
“trans fats” belong to the unsaturated fatty acid family. For example, elaidic acid, 18:1 (trans-9), 
an isomer of OLA, is commonly produced industrially for use in fried fast food, snack food and 
margarine. Although the trans fats are edible, clinical studies have raised concerns because of their 
correlation with coronary heart disease.6  
Elaidic Acid 
Figure 1 Molecular structures of common fatty acids. 
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1.3. Physiological Significance of LCFA’s. 
The Western dietary tradition has been extensively investigated in order to elucidate the possible 
relationships between food intake and human health. The traditional Greenland diet is mainly 
based on fish, seal and whale. Mediterranean food includes not only fish but also vegetables, fruits 
and whole grain. Although their dietary menus overlap, the latter diets are both low in saturated 
fat intake, which as noted above is a risk factor for cardiovascular diseases.7 
A substantial body of research has considered the importance of LCFA in cardiovascular diseases, 
aging and neurodegeneration. Several reports showed that n-3 polyunsaturated fatty acids (PUFA) 
protect against cardiovascular disease by decreasing blood pressure8. For instance, the blood 
pressure was decreased -5.5/-3.5 mm Hg by giving >3 g/d of omega-3 fatty acids9. 
Supplementation with PUFA is thought to be helpful to reduce the risk of cardiologic diseases 
such as hypertension and atherosclerosis.10  
Besides inflammation and cardiovascular health, LCFAs are also very important in the 
construction of neuronal membranes. PUFA are critical in the functioning and development of the 
visual and brain systems.11 During pregnancy the infant brain starts to accumulate 
docosahexaenoic acid (DHA, 22:6 n-3),12 which supports development and rapid growth. A 
deficiency of n-3 PUFAs has been reported to lead to a variety of human neurological diseases 
such as depression, schizophrenia, autism spectrum disorders and anxiety.13 The long-chain 
polyunsaturated fatty acid (LCPUFA) concentration in the human and rodent brain decreases with 
age. Cognitive impairment and inflammation have been studied and reported as tightly correlated 
with the amount of LCPUFA.14 
Since LCFA are quite important in maintaining human health and are implicated in a variety of 
diseases, researchers have tried to understand how they function at the molecular level. It has been 
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clearly established that fatty acids are good energy storage candidates that play an important role 
in energy metabolism. It is also recognized that these molecules bind and interact with many 
enzymes or other proteins which are very important for the regulation of gene transcription and 
lipid metabolism. The LCFAs are able to bind with peroxisome proliferator-activated receptors 
(PPARs), which will be introduced in more detail below. The LCFAs bind and activate almost all 
subtypes (PPAR𝛼, PPAR𝛽/𝛿, and PPAR𝛾), displaying dissociation constants Kd ~1-5 𝜇M that 
indicate moderately tight LCFA-binding interaction and association.15 The reported physiological 
concentrations of non-esterified LCFAs are ~0.1-0.5 mM in liver tissue,16 which is much more 
larger than the Kd value. However, the intracellular concentration of free LCFAs is approximately 
equal or lower than Kd .
17 Meanwhile, there is another protein type, the fatty acid-binding proteins 
(FABPs), which binds the LCFA tightly and is present at levels of at least 1 mM in liver and 
adipose tissues.18 
Finally, there are many other nuclear receptors which can bind the LCFAs, such as liver-X receptor 
(LXR), farnesoid-X receptor (FXR), vitamin D receptor (VDR), retinoic acid receptor (RAR) and 
thyroid hormone receptor (TR).19 LCFAs can bind the hepatocyte nuclear factor 4𝛼 (HNF4𝛼), 
which is a very important coactivator of nuclear receptors.20  
1.4. Biological function and subtypes of FABPs 
Fatty acid-binding proteins (FABPs) belong to the intracellular lipid-binding protein (iLBP) family 
and are involved in binding long chain fatty acids and other water insoluble hydrophobic ligands 
reversibly. FABPs are also used in trafficking and targeting LCFAs into the nucleus, where nuclear 
receptors e.g. the PPAR family bind and activate them. Previous research has found that FABPs 
play an important role in signal transduction pathways, cell growth, cell cycle and 
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differentiation21,22,23, by regulating the concentrations of FAs in the nucleus and ultimately 
affecting the interactions with various nuclear hormone receptors.  
FABPs are low molecular weight (~15kDa) fatty acid carrier proteins, which contain variable 
members, each of which has between 20% and 70% identity in their amino acid sequence. These 
subtypes are named for the organ in which they were first discovered and identified, including 
liver- (L-FABP), heart- (H-FABP), intestine- (I-FABP), adipocyte- (A-FABP), epidermal- (E-
FABP or K-FABP), ileal- (Il-FABP), brain- (B-FABP), myelin- (M-FABP) and testis-FABP (T-
FABP). It is important to be aware that both the AFABP and KFABP (EFABP) are primarily 
expressed24 in the adipocyte which could be candidates to interact with the PPARγ that will be 
discussed later in 1.11. 
An understanding of the requirements for import of AFABP to the nucleus is important in 
understanding the mechanism of how the ligand transfer is transferred to PPARγ. The AFABP 
cannot enter through the nucleus membrane unless it binds an activating ligand e.g. linoleic acid 
(LOLA) to reveal the so-called Nuclear Localization Signal (NLS) sequence. Then, it can be 
transported into the nucleus and pass its bound ligand to target proteins such as PPARγ. When the 
AFABP is in apo form or binds a non-activating ligand such as oleic acid (OLA), the AFABP’s 
NLS will be hidden and the protein will remain in the cytosol25.  
 
1.5. Structures of FABPs 
According to the X-ray and NMR derived structures26 (Figure 2), these proteins have shown a 
common β-clam tertiary structure，which contains two α-helices and ten antiparallel β-sheets. The 
N-terminus of FABPs contains a helix-loop-helix motif which forms a cap-like structure that may 
6 
 
be related to the entering of the fatty acid ligand. A transient conformational change around the 
helix-loop-helix area and their close loops is proposed to occur for some family members, thereby 
allowing the ligand to enter or exit the binding region27. 
Liver FABP (L-FABP) is one of the subtypes of FABP family members. Unlike the other FABPs, 
L-FABP can bind two FAs at maximum. The first ligand binds to L-FABP through the carboxyl 
group interacting with R122, S124 and S39 in the internal binding cavity. The second interacts 
with K31 and S56 which are located at the portal region of the L-FABP28. Binding constants 
between the second ligand and protein are variable. If the second binding ligand is saturated FAs, 
then the protein binds more weakly, in contrast to the indistinguishable binding constants for 
unsaturated FAs. For instance, the second binding site of saturated chain palmitate is 
indistinguishable from the first site with dissociation constant Kd~23±2 nM
29. In contrast, for the 
unsaturated linolenic acid the second binding site is much weaker (1st site Kd~69±12 nM, 2
nd site  
Kd~1000±500 nM)
29. The binding constant of AFABP-linoleic acid is 1.96±0.39 nM30. Although 
the Kd values were reported from different laboratory so that they are not quite comparable, it is 
valuable to be aware of the Kd of FABPs binding the fatty acids in the nano molar range. 
For the apo form of rat LFABP, Stark et al. have reported 109 out of 124 nonprolyl residue (88%) 
of the backbone amide 1H, 15N NMR assignments31. Fifteen missing backbone resonances could 
be attributed to local flexibility (BMRB accession code 4098). Similarly, the 1H, 15N resonances 
of Locusta migratoria FABP were partially assigned (88%) as well by Hamilton et al.32 (BMRB 
accession code: 5541). Six of these unobservable residues (G45, T53, S56, M74, G106, and D107) 
appeared when LFABP was bound to two molecules of OLA28 (BMRB accession code 15429) 
published by Stark et al. An intermediate state designated as the preholo-LFABP was observed by 
stepwise titration of apo-LFABP by OLA. It has been demonstrated that the LFABP can bind up 
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to two fatty acids by isothermal titration calorimetry (ITC) and solution NMR spectroscopy33. An 
“adaptation” of the singly ligand-binding LFABP to the entry of the second OLA into the ligand-
binding cavity was suggested33. The residues R122L/S124A have been mutated to study the 
binding property. The titration result shows that the mutant structure is similar to the wild type, 
but it can only accommodate just one ligand at an intermediate site between the apo and doubly-
holo forms in the binding cavity33.  
A computational study of the “portal regions” reported that there could be an alternative portal for 
the inner ligand to dissociate from the L-FABP binding cavity34. In this research, the highly 
favorable egress of an inner ligand from the second site is claimed to be a specific feature of L-
FABP, contrasting with I-FABP. This portal (Portal II) is related to βE/F loop and α-helix cap 
(Figure 2a), while the anterior portal region (Portal I) is delimited by α-helix II and the βC/βD loop 
(Figure 2b). The inner ligand OLA129 can dissociate from the protein through Portal II 
predominantly, whereas the outer OLA128 still remains bound in the cavity. This newly proposed 
portal region (Portal II) has been reported to release not only linear ligands but also compounds 
with rigid rings i.e. 8-Anilinonaphthalene-1-sulfonic acid (ANS). Portal II may be the main portal 
for the inner ligand dissociation. It is important to consider different portal regions, especially to 



















 Figure 2 Tertiary structure of L-FABP (2JU8) is represented in cartoon by Pymol.Each 
helix and strand (yellow) is indicated with two oleic acid ligands as well, which have been 
labeled as OLA128 and OLA129, respectively. Portal I and Portal II have been marked by 
blue and red unfilled arrows, respectively. b) Expanded view of the ligand-binding pocket 
containing several amino acid side chains that have been labeled. Hydrogen bonds between 
the polar side chains and the oleic acid head group are indicated by yellow dashed lines. 




1.6. Physiological Significance of PPARs 
PPARs were first discovered in Xenopus frogs, where they induce the proliferation of peroxisomes 
in cells.35 Then they were proven to be the target of hepatic peroxisome proliferator and cloned by 
Issemann and Green36. So far it has been discovered that the PPAR protein superfamily contains 
three isoforms: PPAR𝛼, PPAR𝛽/𝛿 and PPAR𝛾.  
 The first member of the family that was isolated and cloned was murine PPAR𝛼36. Subsequently, 
the frog, rat, rabbit and human forms were discovered and cloned37. PPAR𝛼 can be expressed in 
many metabolic tissues such as liver, adipose, heart, kidney and skeletal muscle.38 PPAR𝛼 is a 
potent lipid sensor in the nucleus and an important regulator of cellular lipid metabolism, including 
cellular uptake and 𝛽-oxidation of fatty acids39. PPAR𝛼 has been found to be a target for drug 
design to cure  the dyslipidemia, type 2 diabetes and atherosclerosis40 , in which activation causes 
the lowering of triglyceride levels by cooperation with fibrate therapeutic drugs41. PPAR𝛼 is also 
a modulator of inflammation: the activation of PPAR𝛼 inhibits the inflammatory action of the 
eicosanoids42.  
PPAR𝛽/𝛿 is another subtype of the PPAR family that was subsequently cloned from human, 
Xenopus, mouse and rat sources.43  It has been found to be expressed in brain, adipose and skin 
tissues.44 As for PPAR𝛼, PPAR𝛽/𝛿 has been determined to be related to dyslipidemia. The 
PPAR𝛽/𝛿 agonist GW-501516 can lead to an increase in HDL-cholesterol levels as well as a 
reduction in triglycerides in serum.45 PPAR𝛽/𝛿 could also play a role on cancer: it has been 
reported as a target of Adenomatous Polyposis Coli (APC), which is a tumor suppressor in 
colorectal cancer cells46. Additionally, PPAR𝛽/𝛿 has been found to display the highest expression 
levels in embryonic brain. This latter observation might indicate that PPAR𝛽/𝛿 is related to the 
differentiation of cells within the central nervous system (CNS)47.  
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The third member of the family is PPAR𝛾, which is expressed in a broad range of tissues including 
heart, skeletal muscle, colon, kidney, small intestine and adipose types. Previous research has 
found that PPAR𝛾 is required to differentiate the adipocyte cells.48 Moreover it has been found as 
a antidiabetic target to increase the insulin sensitivity for type 2 diabetes mice.49 The PPAR𝛾 
agonists can stimulate insulin action.50 In addition, previous results from cancer studies show that 
PPAR𝛾 ligands inhibit cell proliferation when adipocyte differentiation is induced.51 It has been 
found that PPAR𝛾 expression is increased above the normal level in cancer cell lines.52 Some 
researchers found that treatment with high doses of the drug troglitazone produces a small increase 
in tumor growth,53 but others found that treating mice with troglitazone can inhibit the growth of 
transplanted human tumors.54 Although it is still uncertain how the PPAR𝛾 functions in tumor 
proliferation, it appears to display a significant influence on cancer mechanisms. 
 
1.7. Molecular Structure of PPARs. 
Although these protein subtypes express and accumulate in different tissues, they share very 
similar conserved tertiary structure and functional domains. PPARs contain three functional 
domains (Figure 3). The N-terminus is designed as the AF-1 (A/B) domain, which is a ligand-
independent functional domain. It is followed by a DNA binding domain (DBD) that binds PPAR 
Response Elements (PPRE) of specific targeted gene sequences. After a hinge connection, there is 
a ligand binding domain (LBD), which contains an AF-2 (ligand-dependent activation functional 
domain) located at the C-terminus of the polypeptide55. 
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Figure 3 Conserved functional domains of the PPAR family.They include an AF-1(A/B) 
domain at the N-terminus (red rectangle), a DNA binding domain (DBD, marked as a blue 
rectangle) and a ligand-binding domain (LBD, marked as moss green) at the C-terminus, 
where there is a activation function domain (AF-2) belonging to the LBD. There is a short 
hinge between the DBD and LBD.  
 
PPARs, as transcriptional factors, usually work by forming a heterodimer with nuclear hormone 
receptors such as the RXRs, combined with zinc ions and their functional ligands (Figure 4). This 
heterodimer recognizes and binds the specific DNA regions termed PPREs, which contain 
consensus direct repeats of AGGTCA or TGACCT that are recognized and bound by the PPAR-
RXR heterodimer56 (Figure 4). For instance, Acyl-CoA oxidase (TGACCTTTGTCCT) or Acyl-
CoA synthetase (TGACTGATGCCCT) have been implicated. Generally this sequence occurs 
mainly in the promoter region of the gene. When the PPAR binds its ligands, the subsequent 
transcription will be regulated, either activated or inhibited, depending on the ligand binding.  
When natural ligands or agonists bind, the conformation of the PPAR, namely the AF-2 (helix 12, 
H12) direction and position, is changed and stabilized, thereby initiating the recruitment of 
transcriptional coactivators (Figure 4, yellow ribbon).57 Antagonists that prevent the PPARs from 
recruiting the coactivators force AF-2 to occupy the coactivator binding site.57 For example, 
leukotriene B4 (LTB4) was found to be a PPARα ligand,58 which was proposed to inhibit 




1.8. Structure of the PPAR ligand-binding domain 
 According to X-ray crystallographic studies, the structure of the hPPARα LBD is very similar to 
the hPPARβ LBD and hPPARγ LBD. 59 As noted above, the PPARα ligand binding domain is 
composed of 12 antiparallel helices packing a 3- antiparallel β sheet core (some references consider 
that there is one more sheet between H5 and S23 composed of amino acid residues MSKD in 
PPARα LBD, VNKD in PPARδ LBD, MNKD in PPARγ LBD) (Figure 5). The greatest deviation 
among these three sub-types occurs for residues 231-265, which is referred to as a loop. Residues 
449-457 belong to the C-terminal AF-2 helix, which also varies among these three subtypes.  
LXXLL 
LXXLL 
Figure 4 X-ray crystal heterodimer of the intact PPAR𝛾-RXR-nuclear receptor complex 
on DNA (3DZU).The retinoic acid receptor RXR-α is marked in green. PPARγ is indicated 
by magenta ribbons. DNA chains associated with the heterodimer are shown in cyan and 
light pink. There are four white spherical dots indicating zinc ions bound to the 
heterodimers. Each of their ligands has been shown in stick format (retinoic acid: white 
stick, 2-[(2,4-dichlorobenzoyl)amino]-5-(pyrimidin- 2-yloxy)benzoic acid): yellow stick). 
LXXLL motifs of a steroid receptor coactivator have been marked with short ribbons 
designated in yellow (bound to PPARγ) and white (bound to RXRα) 4.     
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The ligand binding site is located at the very center core of the LBD, which is highly hydrophobic. 
Most of the residues in the binding cavity are conserved across the three subtypes. It is interesting 
to notice that there are four conserved polar residues which are part of the hydrogen-bond network 
involving the carboxylate group of the FA and eicosanoic acid ligands3 (Figure 5b). The interacting 
residues are Ser280 (H4), Tyr314 (H6), His440 (H11) and Tyr464 (H12) of PPARα (respectively 
Thr289, His323, His449 and Tyr473 of PPARβ, and Ser289, His323, His449 and Tyr473 of 
PPARγ). The entrance to the ligand binding site is between H3, H4, the N-terminus of H6 and the 







Figure 5 C rystal structure of PPARαLBD (2GWX) represented by Pymol.a) (H1-navy, H2-
royal blue, H3-teal blue, H4-mint, H5-emerald, H6-spring green, H7-lime green, H8-light 
yellow, H9-marigold, H10- brown, H11-orange, H12 (AF-2)-red).  b) Expansion of the 
ligand binding cavity. Each of the related residues and their side chains are labeled and 
separated by various colors. The hydrogen bond interactions are indicated by yellow 




1.9. PPAR-binding ligands 
PPARα can be activated to dissociate from corepressors and recruit coactivators, which associate 
with histones of DNA and thus allow RNA polymerase to transcribe mRNA, by binding a broad 
range of fatty acid ligands, including palmitic acid, oleic acid, linoleic acid, and arachidonic acid60. 
The activating ligands include linoleic acid (18:2)61 and linolenic acid (18:3)62. There are some 
non-activating ligands which can bind the PPARα LBD as well, such as palmitic acid. (16:0) 63 
The dissociation constants are shown in Table 1 below.  
Since both the PPARs and FABPs bind lipids tightly, it is necessary to choose an appropriate 
measurement method. The most commonly used methods to measure the binding dissociation 
constant are AcryloDan labeled Intestinal Fatty Acid Binding protein (ADIFABP), fluorometric 
displacement assay and fluorescence competition titration. ADIFABP is an indicator developed by 
Dr. Alan Kleinfeld that can bind the free fatty acid in solution. Detection of FFA by ADIFAB is 
based on a change in the position of the acrylodan fluorophore relative to the nonpolar binding 
pocket of the protein when it becomes occupied by a fatty acid (FA). All of the methods are quite 
sensitive to reach Kd ~1 𝜇M. Specifically, the ADIFABP assays can reach Kd ~1 nM on basis of 
the reports in Table 1. Notably, the values for Kd obtained from different methods are widely 
different. For example, the Kds for L-FABP binding oleic acid are determined as 9 nM and 1.8 𝜇M 
using ADIFABP assay and Lipidex separation, respectively. Since the experiments are not 
measured by the same instrument or performed by the same person, the values are not comparable. 
Thus, if it is required to compare the binding affinity between FABPs and PPARs, it is necessary 
to perform the experiment using the same instrument and under comparable conditions (e.g. buffer 
condition and ligand batch).For instance, according to the table 1, only the binding affinities to 
cis-Parinaric acid ligand are comparable because they are measured by the same methods from the 
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same laboratory. According to this measurements, it is known that the binding constants of 
AFABP-cis Parinaric acid and PPARγ- cis Parinaric acid are in the same magnitude ~40 nM. The 
PPARγ- cis Parinaric acid constant is slightly bigger than the AFABP- cis Parinaric acid constant.   
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 Table 1. LCFA Ligands and their binding constants with PPAR𝛾 and A-FABP proteins 
 
Ligand A-FABP / Kd ± S.E. PPAR𝛾/ Kd ± S.E. 
          nM           nM 
Palmitic acid 3.36 ± 1.64a 156000 ± 4720 e 
 7.7  ± 0.15 b  
 1.54 ± 0.11 c  
Oleic acid 1.85 ± 3.5a  
 0.61 ± 2.5 b  
 1.19 ± 0.19 c  
Linoleic acid 1.01 ± 0.12 b 1300 ± 84 e 
 3.22 ± 0.10 c 4900 ± 2100 e 
Stearic acid 0.76 ± 0.15 b  
Docosahexaenoic acid 1.07 ± 0.21 b  
Linolenic acid 1.96 ± 0.39 b  
Arachidonic acid 1.39 ± 0.28 b  
 5.80 ± 0.26 c  
cis - Parinaric acid 31.7 ± 2.3 d 49.6 ± 1.2 d 
 7800 ± 240 e  
Troglitazone  274 ± 0.142 e 
 
a 1,8-ANS (8-anilino-1-naphthalene-sulfonic acid) displacement assay64  
b ADIFAB assay65 
c ADIFAB assay66 
d Fluorescence competition titrations67 






The molecules shown in Table 1 are PPARα ligands based on previously published research.69 
Most of the molecules share a similar long alkyl chain.70,71,72,73,74 An activating ligand is 
understood to be a molecule that increases the expression of a gene, which has been targeted and 
is regulated by PPARα. This process is known as transactivation. Transactivation assays are 
applied to cells that have been transfected with a vector expressing PPARα as well as a second 
vector containing a PPRE and a reporter gene, which encodes an enzyme such as luciferase.75 The 
activity of a ligand will then correlate to the resultant luciferase activity. 
 
1.10. PPAR Functional Partners 
1.10.1. Secondary and tertiary structure 
PPARs have been observed to interact with many other polypeptides, such as the steroid receptor 
co-activator-1 (SRC-1) and CREB-binding protein (CREBBP), which are two co-activators76. The 
recruitment of these co-activators depends allosterically on the conformation of the AF-2 domain, 
which is stabilized by binding an activating ligand such as rosiglitazone. When PPARs bind the 
activating ligands, the AF-2 domain will be stabilized and exposed to the hydrophobic surface, 
where the LXXLL helix of the co-activator can interact and form a complex, for example 
PPAR𝛾/rosiglitazone/SRC-13.  
When antagonists are bound to PPARs, they push the AF-2 helix away from the agonist bound 
position. This causes the AF-2 domain to pack loosely against helix 3, instead of occupying the 
co-activator-binding groove. As a result of removing H12 from the active surface, there is more 
space for binding the co-repressor motif, LXXXIXXXL3. The latter binding motif prevents the 
AF-2 from moving back to an activating conformation.  
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Another important receptor protein, RXR𝛼, is found to form a heterodimer with PPAR𝛾 LBD. By 
interacting with the RXR𝛼, the complex can function as a transcriptional regulator that activates 
or inhibits the target gene transcription. The interface occurs between the Lys431 of RXR𝛼 and 
Tyr477 of PPAR𝛾77. This arrangement can be strengthened by another interaction pair (PPARγ 
Tyr477 and RXRα Arg348). This can stabilize the PPAR AF-2 in a position that allows the co-
activators to bind and function even without binding agonists.  
Figure 6. The residues and structures of PPARγ involved in activating function. (A) PPARγ 
residues involved in a hydrogen-bond network stabilizing the AF-2 domain in a ligand-
independent manner (2PRG [1]). Hydrogen bonds are shown as thin green lines. AF-2 helix 
H12 is colored in orange. (B) Interactions between residues Leu469, Tyr473, Leu476 and 
Tyr477 (in dark ball and stick) and some neighboring residues of PPAR that stabilize the 
active conformation of AF-2 helix H12 (colored in neons). Rosiglitazone is also shown 
(magenta in red box). 
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1.10.2.   Open questions about the PPARs delipidation 
In none of the previous studies on PPARs have they been demonstrated to be unliganded (apo) 
before the subsequent research. It has never been claimed that the PPARs are treated to empty the 
binding cavity, which usually contains some lipids from host cell lines e.g. E. coli. The expressed 
and purified proteins are assumed to be in “apo form” without adding ligand artificially, but this 
unverified assumption ca nlead to misinterpretations. For instance, the reported ligand binding 
constant will be a “replacing Kd” that is related not only to the titrated ligand but also to the 
remaining ligand from the host cell lines. Even worse, if the titrated ligand binding is weaker than 
the remaining one, then the final protein will be a mixture of holo forms binding more than one 
ligand. Thus, this problem will introduce an error during further studies of structure or activity.  
A single literature report has attempted to delipidate PPARs by loading the protein solution on the 
prepacked hydrophobic interaction (HIC) column at 37  ̊C78. Since the HIC column is made of a 
fairly hydrophobic material, it should compete for the lipids against the proteins. To date, however, 
there is no report demonstrating a successful delipidation of a PPAR. In this project, we will 
discuss several ways to delipidate the PPARs by optimizing the conditions based on previous 
references. 
 
1.10.3. Open questions about PPAR NMR assignments 
In addition to the crystal structures presented in Section 1.4, it is possible to study the molecular 
structure of PPAR𝛾 using solution-state Nuclear Magnetic Resonance (NMR) spectroscopy. Since 
the protein functions in solution state, it is sensible to study its protein-protein and protein-ligand 
interactions by using solution-state NMR. So far, there are only four sets of PPAR NMR 
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assignments published in the Biological Magnetic Resonance Data Bank (BMRB). All of these 
assignments pertain to the holo-PPAR𝛾 LBD subtype bound to GW1929, rosiglitazone, MRL24 
or MRL20 (BMRB: 15518, 17975, 17976 and 19777). 
1.11. Interactions between PPARs and FABPs 
Recently, many observations have been made that help to explain the mechanisms and pathways 
by which fatty acids as signaling molecules target and regulate lipid metabolism. First is that both 
PPARs and L-FABP co-localize in the nucleus79. L-FABP as a fatty acid-binding protein is 
abundant in the cytosol, but it has also been discovered in the nucleus where PPARs predominantly 
localize. A second observation is that some portion of L-FABP binding and transferring ligands 






Figure 7. Spectra and structure mapping published by Dr. Tony Velkov. (a) 1H-15N HSQC 
spectrum of 15N apo-L-hFABP overlaid at the bottom of the spectrum of 15N LFABP titrated 
by holo-PPARα LBD(blue). (b) The highly perturbed residues (>0.6 p.p.m perturbation) 
titrated by holo-PPARα LBD are mapped onto the crystallographic structure of human L-
FABP (PDB code: 2F73)1 and colored by red. 
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dissociation constants in the micro- or nanomolar range, is transferred by L-FABP80. Finally, L-
FABP expression and β-oxidation enzymes are induced by hypolipidemic drugs through PPARα80.  
Only one report by Velkov et al. has appeared about the interaction between L-FABP and PPARα1 
using the solution-state NMR technology (Figure 7). These investigators claimed that the 
LFABP1H-15N HSQC spectrum was significantly perturbed by titrating with PPARα (Figure 7a). 
All of the largely perturbed residues identified in his paper have been mapped onto the structure 
of the LFABP (Figure 7b). However, we would expect broader HSQC peaks for the 50-kDa FABP-
PPAR complex and would benefit from the use of TROSY-HSQC strategies (REF).  The data 
obtained so far should be viewed with caution. Thus, in sum, the mapped structure of the 
perturbation is inconclusive and need to be studied further more. 
Despite a broad range of evidence that supports the possible interaction between L-FABP and 
PPARα, there was no consensus until it was reported that L-FABP interacts directly with PPARs5 
using the methods of immunoprecipitation, Western immunoblotting, Northern-blot analysis and 
a mammary epithelial cell proliferation assay (Figure 8). Before that it was simply believed that 
FABP works as a fatty acid transporter. Aqueous diffusion of these ligands, which are not 
hydrophilic, can be facilitated with the help of FABPs81. It was discovered that I-, H- and A-FABP 
can lead to the dissociation of fatty acids from model membranes82, while some recent reports 
found that L-FABP associates with specific nuclear membrane proteins when PPAR ligands are 
present 83.  
Direct evidence for this protein-protein interaction came from immunoprecipitation of L-FABP 
and PPARα5. According to Figure 8A, either an antibody to PPARα or an antibody to L-FABP 
was used. Both proteins were pulled down by the antibody, suggesting that L-FABP interacts with 
PPARα directly in vitro. Meanwhile, experimental results showed that only the pairs (α-PPARα, 
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L-FABP) and (α-L-FABP, PPARα) display a positive immunoprecipitation band (Figure 8A). This 
proved that the binding between L-FABP and PPARα and the binding between A-FABP and 
PPARγ is specific.  
 
Another line of research showed that L-FABP and A-FABP can respectively interact with PPARα 
and PPARγ, with or without ligand addition80. By further studying the interaction between these 
proteins, scientists provided more evidence that cooperation between FABPs and PPARs is highly 
selective84. That is, PPARγ can be activated by A-FABP, while PPARβ can be enhanced in activity 
by K-FABP. According to the Figure 9D, the AFABP can transfer the ligand (troglitazone) to 
PPARγ, but the KFABP cannot. This is another evidence that the interaction between the AFABP 
and PPARγ is specific, although the AFABP and KFABP are both primarily expressed in adipocyte. 
More reports provide evidence that L-FABP directly interacts with PPARα and is involved in the 
Figure 8. Co-immunoprecipitation of L-FABP and PPARα recombinant proteins. A: L-
FABP and PPARα proteins (20 𝜇g each) were mixed, immunoprecipitated with anti-PPARα 
(α-PPARα) or anti-L-FABP (α-L-FABP), and examined by SDS-PAGE and Coomassie blue 
staining for each protein. B: L-FABP and SREBP-1a proteins (20 𝜇g each) were mixed, 
immunoprecipitated with anti-SREBP-1 (α-SREBP-1) or anti-L-FABP (α-L-FABP), and 
examined by SDS-PAGE and Coomassie blue staining for the presence of each protein. C: 
SREBP-1a and PPARα proteins (20 𝜇g each) were mixed, immunoprecipitated with anti-
SREBP-1 (α-SREBP-1) or anti-PPARα (α-PPARα), and examined by SDS-PAGE and 
Coomassie blue staining for the presence of each protein.5 
23 
 
nucleo-cytoplasmic shuttling of their ligands85,86,60, which are found within the binding pocket of 
L-FABP and the ligand binding domain of PPARα. As PPAR LBD is sufficient for interacting 
with the FABP39,87, most of the proposed research focuses only the interaction between the PPAR 







Figure 9 A-FABP directly channels troglitazone to PPARγ-LBD, while K-FABP does not. 
The dependence of the rate of transfer of troglitazone (TZD) from FABP to PPARγ was 
examined. PPARγ-LBD was covalently labeled with a pyrene moiety. (A) The labeled protein 
(1 μM) was titrated with A-FABP precomplexed with troglitazone. Fluorescence (λex = 342 
nm; λem = 377 nm) decreased upon titration until a plateau was reached at saturation. (B and 
C) To determine the rate constants for ligand transfer from FABP to PPARβ-LBD, pyrene-
labeled PPARβ-LBD was mixed with A-FABP (B) or K-FABP (C) precomplexed with 
troglitazone. Mixing was accomplished using a stopped-flow apparatus. Final protein 
concentrations for the representative traces shown were 1 μM PPARβ-LBD and 5 μM FABP-
ligand complexes. Traces were analyzed by fitting to a single first-order reaction (solid line 
through data points) to obtain the pseudo-first-order rate constant of the reaction. (D) t1/2 
for transfer of troglitazone from A-FABP (solid circles) or K-FABP (open circles) to PPARβ-
LBD as a function of the FABP/PPAR molar ratio. 
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Finally, more evidence has been supplied to prove and quantify this interaction between PPARα 
and L-FABP both in vitro and in vivo5. Schroeder et al. quantitatively analyzed this direct 
interaction with the method of Fluorescence Resonance Energy Transfer (FRET)5 and obtained a 
PPARα--L-FABP complex dissociation constant Kd = 156.5 ±18.1 nM with the application of 
sensitized emission of Cy3-apo-L-FABP and Cy5-apo-PPARα (the Cy dyes are fluorescent 
cyanine compounds producing an intense signal that can be detected). This result not only 
demonstrated an important interaction but also revealed that the associated binding affinity was 
moderately strong. 
1.12. Open questions about PPARs interaction with FABPs 
According to previous research, it has been demonstrated that the PPARs can form complexes with 
FABPs in vivo. It has also been found that the PPAR𝛼 LBD specifically binds L-FABP, and the 
PPAR𝛾 LBD specifically binds A-FABP. But it is unknown which parts are the actual interacting 
surfaces on both proteins pairs and whether the interaction functions to promote the ligand transfer 
between the PPARs and FABPs. Since PPARs are mainly located in the cell nucleus, the ligand 
transfer is an important problem to solve. FABPs as one kind of lipid carrier can transfer in both 
the cytosol and nucleus. Meanwhile, the FABPs have been shown to form a specific complex with 
PPARs. It is unknown but interesting that whether the interaction between these proteins is related 
to the ligand transfer or not. Studying the possible ligand transfer is important and helpful to 
understand many biological pathways e.g. the regulation of lipid metabolism. This type of study 
is also promising for the design of pharmaceutical drugs, in that analogs of the native ligands could 
activate or inhibit the corresponding ligand transcription. In sum, studies of the interaction between 
these two proteins and the process of the potential ligand transfer is worthwhile to aid in 
understanding the signaling pathways that regulate lipid metabolism. 
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2. MATERIALS, PROCEDURES, AND RATIONALE 
A description of the AFABP purification, delipidation, and oligomerization procedures has been 
published:  Q. Wang,* S. Rizk,* C. Bernard, D. Kam, J. Storch, and R. E. Stark, “Protocols and 
Pitfalls in Obtaining Fatty Acid-Binding Proteins for Biophysical Studies of Ligand-Protein and 
Protein-Protein Interactions,” Biochem. Biophys. Rep., 10, 318-324 (2017). 
2.1. Molecular cloning of the target proteins 
2.1.1. Molecular cloning of the PPAR LBDs 
2.1.1.1 Molecular recombination 
The PPAR𝛼 LBD gene sequence (cDNA) is carried on the pCMX plasmid supplied by Dr. Judith 
Storch’s group. In order to overexpress and obtain enough protein for further studies, the 
corresponding gene needs to be combined into an expression plasmid which contains a 
transcription promoter, ribosome binding position and affinity tag (6 x His-tag in this project). A 
mature Invitrogen Gateway® system was employed to accomplish the re-combination. First, the 
target cDNA sequence was obtained and amplified by the polymerase chain reaction (PCR) with 





The PCR product was purified by using an Invitrogen PCR product purification kit and introduced 
into the expression plasmid pET-57-DEST (or pDEST17) by the Gateway® reaction kit 88 (Figure 
10). The reason we chose the pET-57-DEST plasmid is because it can link our PPARs with a 
fusion protein NusA at the N-terminus, so as to increase the PPAR solubility during the 
overexpression. The final expression clone was sent to Genewiz for sequencing to confirm our 
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target protein sequence. Additionally, the PPAR𝛾 LBD recombination was achieved by Dr. Cédric 
Bernard in an analogous way.  
2.1.1.2 Transformation 
The successfully recombined expression clones, including FABPs and PPARs, were transformed 
into two alternative competent cell lines: BL21-AITM and BL21(DE3)pLysS by following the heat-
shock procedure. Each of the cell lines has a different protein inducing system. BL21-AITM has 
the tightly regulated arabinose-inducible araBAD promoter upstream of the T7 RNA polymerase 
gene. BL21(DE3)pLysS recruits the lacUV5 promoter which is suitable for production of protein 
from target genes cloned in pET vectors by induction with Isopropyl β-D-1-thiogalactopyranoside 
(IPTG).   
Once the competent cells were transformed, the cell medium was placed on the LB agar plates 
with antibiotics, which depends on what plasmid was used. The plates were incubated for 15 hours. 
Then a single colony was picked and inoculated into LB liquid medium with the same antibiotics. 
This pre-culture medium was shaken at 37 ̊C at 225 rpm for 15 hours. The harvested culture was 
used for a large culture (1 liter) or stored at -80 ̊C with addition of 5% glycerol.  
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2.1.2. Molecular cloning of the FABPs 
The FABPs (AFABP and LFABP) were recombined in the same way shown above. The only 
difference was that the FABP sequences were finally introduced into the pDEST17 plasmid instead 
of pET-57-DEST. Compared with the pET-57-DEST, the pDEST17 links the His-tag to the FABPs 
directly, because FABPs do not encounter a problem of solubility. More details will be presented 
in a later section of this thesis. 
2.2. Protein expression and purification 
2.2.1. Expression and purification of the FABPs 
A BL21-AI-FABP pre-culture was inoculated to a large size medium at 50 times dilution so as to 
grow a large amount of cells producing our target protein. The Luria-Bertani medium (LB, Sigma 
L3022) is used for generating unlabeled proteins, while the minimal medium (0.4% 12 or 13C-
Figure 10. Flowchart for the molecular recombination of FABPs and PPARs. 
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glucose, 2 mM MgSO4, 0.1 mM CaCl2, 100 𝜇g/mL ampicillin, 1x sigma MEM vitamins solution, 
20 mM KH2PO4, 450 mM Na2HPO4, 8.5 mM NaCl, 1g/L 
14 or 15N-NH4Cl, pH 7.2) is used for 
producing 13C and/or 15N labeled proteins. The culture was shaken under the same conditions as 
the pre-culture until the OD600nm (absorbance) reached ~0.600. Then 2.0% L-arabinose was added 
to activate the araBAD operon, so that a large amount of T7 RNA polymerase would be generated 
to recognize our promoter and therefore start the transcription of our target FABPs. The inducer-
treated culture continued to grow for another 4 hours or until the OD600nm reached the plateau of 
the sigmoid curve. Then the cell culture was centrifuged at 4000 rpm and 4 ̊C for 30 minutes. The 
cell pellets were frozen at -80 ̊C immediately or suspended for subsequent lysis. According to this 
protocol, ~6 grams of cells were harvested from 1 liter culture. 
The 6 grams of cell pellets were suspended with 50 mL Lysis Buffer (50 mM Tris-HCl, 150 mM 
NaCl, 10 mM imidazole, 1 mM phenylmethane sulfonyl fluoride (PMSF), 1 mM 
ethylenediaminetetraacetic acid (EDTA), pH 8.0). Sonication to produce a lysate was done by 
using a Misonix Sonicator-3000 for 45 minutes at 30 watts power. The lysate was centrifuged to 
recover the supernatant. Filtration of the supernatant was done with 0.20 𝜇m Millipore filters for 
the subsequent HisTrap chromatography.  
Affinity purification was performed on a HisTrap HP 5 mL column (GE Healthcare) which was 
attached to an Äkta purifier Fast protein liquid chromatography (FPLC) system (GE Healthcare). 
Since the nickel charged HisTrap column can specifically bind His-tagged proteins, once the lysate 
supernatant flows through the HisTrap column, only our protein will bind. The column was pre-
equilibrated with a Binding Buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM imidazole, 1.0 mM 
EDTA, pH 8.0). In order to recover our sample protein, a concentration gradient of imidazole (10-
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500 mM) in Elution Buffer (50 mM Tris-HCl, 150 mM NaCl, 500 mM imidazole, 1.0 mM EDTA, 
pH 8.0) was employed to compete with our protein and therefore elute it. 
Usually, there are some contaminants remaining after the HisTrap elution due to non-specific 
binding. In order to further purify the samples, gel-filtration chromatography 89 was conducted to 
separate the proteins by size. A 20-mL portion of the HisTrap eluate was injected into a Superdex 
75 packed XK26/100 column (GE Healthcare). The FPLC was used to pump the sample and GF 
buffer (10 mM potassium phosphate, 150 mM potassium chloride, 0.2 g/L sodium azide, pH 7.4) 
at a flow rate of 0.6 mL/min and a total volume of 700 mL. Different proteins are eluted based on 
their sizes, with smaller proteins eluted out later than bigger ones. Any proteins with size bigger 
than 75 kDa are washed out at the void volume together.  
In order to track the sample quality, sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) was used. First, the samples were collected from each step of the purification. Then 
they were mixed with the sample buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 25% 
β-mercaptoethanol, 1% bromophenol blue) and boiled in a water bath for 5 minutes to fully 
denature the proteins. A 5 𝜇L portion of the mixture was loaded into the SDS-PAGE gel wells and 
run at a voltage of 100 V. The current was stopped when the bromophenol blue leading edge 
migrated to the bottom of the gel. Staining of the gel was conducted in a Staining Buffer (0.1% 
w/v Brilliant Blue, 50% v/v Methanol, 10% Acetic acid) for 1 hour, and destaining of the gel in 
Destaining Buffer (25% v/v Methanol, 10% Acetic acid) was done until the protein bands appeared 
clearly (~ 15 hours). Since the proteins were denatured for SDS-PAGE, the protein size is the only 
factor that impacts the migration rate. Smaller proteins migrate faster and show up close to the 
bottom of the gel. By comparing their positions with the protein standard marker ladders, it is 
straightforward to estimate the size corresponding to each band. 
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After the GF purification, the protein was checked for purity by SDS-PAGE. The His-tag was no 
longer required, so Tobacco Etch Virus (TEV) protease was incubated with the target protein at 
mass ratio (1:10) to remove the His tag. Meanwhile, a 10 kDa Millipore filter was used to remove 
the cut linker (3.5 kDa) as soon as possible to avoid competitive binding with the TEV protease. 
After completing the TEV digestion, the HisTrap column was used to extract the pure FABPs, 
since only pure FABPs lacked the His-tag. The resulting FABPs were checked for purity by SDS-
PAGE. The typical yield was 30 mg per liter of cell culture. 
 
2.2.2. Expression and purification of the PPAR LBDs 
Since PPAR proteins are not as stable as FABPs, an expression and purification procedure similar 
to the one described in last section was used with minor modification. The BL21(DE3)pLysS-
PPARs cell line was grown at 37  ̊C and initially inoculated into the LB medium  (minimal medium) 
for unlabeled (labeled) protein. When the OD600nm absorbance reached ~0.600, the culture was 
chilled on an ice bath for 10 minutes. Then 1.0 mM IPTG with 0.5 mM OLA was added to activate 
the lac operon and meanwhile release the lac inhibitor blocking the RNA polymerase movement. 
The induced culture was continuously incubated at 18 ̊C for another 20 hours or until the OD600nm 
reached the plateau of the sigmoidal curve. Then the cell culture was centrifuged at 4000 rpm and 
4 ̊C for 30 minutes. The cell pellets were frozen at -80 ̊C immediately or suspended for subsequent 
lysis. According to this protocol, ~6 grams of cells were harvested from 1 liter of culture. 
The cell pellets were suspended with 50 mL Lysis Buffer (0.5% Tween20, 5% Glycerol, 50 mM 
Tris-HCl, 150 mM NaCl, 10 mM imidazole, 1.0 mM MgSO4, 5 𝜇g/mL DNAse I, cocktail protease 
inhibitor (Sigma S8830), 1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0). Sonication to 
produce a lysate was done with a Misonix Sonicator-3000 for 45 minutes at a power of 30 watts. 
32 
 
The lysate was centrifuged to recover the supernatant. Filtration of the supernatant was done with 
0.20 𝜇m Millipore filters for the subsequent HisTrap chromatography.  
The supernatant was loaded into a HisTrap column that had been pre-equilibrated by a Binding 
Buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM imidazole, 1.0 mM EDTA, 5% Glycerol, 0.5% 
Tween20, pH 8.0). In order to recover our sample protein, a concentration gradient of imidazole 
(10-500 mM) in Elution Buffer (50 mM Tris-HCl, 150 mM NaCl, 500 mM imidazole, 1.0 mM 
EDTA, 5% Glycerol, 0.5% Tween20, pH 8.0) was employed to compete with our protein and 
therefore elute it out. 
The purified protein from the HisTrap column was injected into the Superdex 75 packed XK26/100 
column (GE Healthcare) in order to exchange the buffer from Tris-HCl to a phosphate buffer 
system. The phosphate buffer system is required for the subsequent TEV protease cleavage and 
for recording of the NMR spectrum. Meanwhile, the GF can further remove the contaminant 
proteins based on size. The GF buffer contains 10 mM potassium phosphate, 150 mM potassium 
chloride, 0.2 g/L sodium azide, pH 7.4. The elution fractions were collected and run by SDS-
PAGE to verify the purity of the sample. 
The purified sample was incubated with TEV protease including 0.5 mM EDTA and 0.5 mM 
TCEP, so as to remove the fusion protein and His-tags connected at the N-terminal of the target 
protein. The mixing ratio of the TEV protease and target protein was 1:10 (g/g). The mixture stayed 
at 4 ̊C for two days or until the linkers were fully removed by the TEV. This result was verified by 
harvesting aliquots every day and running SDS-PAGE. As the digestion proceeded, the gel band 
corresponding to the recombined protein became thinner and eventually disappeared. Since all of 
the components had a His-tag except the cleaved PPARs, only the well-cleaved PPARs flowed 
through a HisTrap column. The other proteins (TEV protease, removed linker, uncleaved PPARs) 
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bound to the HisTrap column. The purified protein amount was measured by a UV spectrometer 
at wavelength of 280 nm and converted to protein mass based on the molar extinction coefficient 
(PPAR𝛼: 10430 M-1cm-1; PPAR𝛾: 11920 M-1cm-1) and molar mass (PPAR𝛼: 30745.9 g mol-1; 
PPAR𝛾: 31052.1 g mol-1) (ExPASy – ProtParam tool). The yield was ~70-100 mg per liter of 
culture.  
 
2.3. Protein delipidation 
2.3.1. Delipidation of FABPs 
Since FABPs can bind lipids which are generated by E. coli cells, it is necessary to remove them 
before conducting further structural studies. The method we use is Lipidex-5000 (Sigma, H6383) 
competitive binding. The Lipidex-5000 resin is a lipophilic Sephadex LH−20−100 (hydroxypropyl 
beaded dextran) which has been substituted with long-chain (C13−C18) alkyl ethers. 5 grams of dry 
Lipidex-5000 were immersed in 5 mL GF buffer to fully activate the beads. Then 40 mL protein 
solution (50 mg protein) was mixed and shaken at 225 rpm and 37 ̊C for 2 hours. The beads were 
removed by using a 0.22 𝜇m filter. The treatment was repeated to fully delipidate the FABPs. For 
AFABP delipidation, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP) reducer is recommended to 
prevent possible homodimer formation. The efficiency of the delipidation was verified by 
subsequent 1H-15N HSQC NMR experiments described below.  
 
2.3.2. Delipidation of PPARs 
In order to study the PPAR ligand binding cavity and corresponding features, it is first necessary 
to obtain apo-PPAR samples. Generally, during expression and purification, there are some lipids 
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from the host cells bound to PPAR. In another words, after purification, the PPAR is actually in a 
holo form carrying various lipids from the expression cell line (E. coli in this project). Thus, it is 
necessary to remove the unknown lipids before we continue the ligand titration or other structural 
determinations.  
Based on previous literature, there are several common ways to delipidate the target protein. One 
way is to partially unfold the protein by treating with a concentration gradient of urea. The 
advantage is that once you destroy the binding cavity, the binding ligand will be released 
completely. But it is tricky to refold the protein correctly. Alternatively and more commonly, one 
can let the protein solution flow through a hydrophobic column. Since the binding ligands are 
usually highly hydrophobic, the column materials will compete with the PPAR to bind the ligand. 
This latter procedure is much gentler to the protein; it will not lead the protein to denature or 
precipitate, provided that the apo form is stable. The column can also be connected conveniently 
to an FPLC purification system. Velkov, et al.78 employed a Hydrophobic Interaction 
Chromatography (HIC) column1 to remove the ligand from the PPAR binding cavity, though no 
validation tests were presented. Other candidate are Lipidex-1000 or Lipidex-5000, which could 
also remove the ligand by hydrophobic competition.  
In this project, we designed another method to delipidate our PPAR because neither HIC nor 
Lipidex removed the bound lipids from the protein cavity. Our method first requires preparation 
of the apo-AFABP following the protocol of FABP delipidation described above. It has been 
observed that AFABP can interact with PPAR𝛾, so the rationale was that apo-AFABP could 
compete with PPAR𝛾 for lipid binding. PPAR𝛾 and apo-AFABP were mixed at a molar ratio of 
1:2 at room temperature. Then the mixture was separated by flowing through a Superdex75 GF 
column at a flow rate of 0.35 mL/min. The PPAR𝛾 fractions were pooled and re-collected. The 
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cycle was repeated with new apo-AFABP for twice in total. The successful isolation of apo-
PPAR𝛾 was verified by detecting the remaining lipids using ESI-MS in the negative ion mode 
(refer to 2.5.2.).  
2.4. NMR spectroscopy 
2.4.1. NMR sample preparation 
15N labeled FABPs were exchanged with an NMR buffer (10 mM potassium phosphate, 150 mM 
potassium chloride, 0.2 g/L sodium azide, pH 7.4) by using Millipore Amicon Ultra-15 Centrifugal 
Filter Units. Then the sample solution was concentrated to approximately 200 𝜇M AFABP for 1H-
15N HSQC NMR experiments. 10% D2O was used for the spectrometer lock signal. The final 
volume of the sample was 450 𝜇L for Shigemi Ultra Precision NMR sample tubes or at least 300 
𝜇L for Shigemi Advanced NMR microtubes.  
2.4.2.  [1H-15N] Heteronuclear Ssingle Quantum Correlation (HSQC) NMR 
Running a 1H-15N HSQC NMR experiment is a simple and efficient way to check the sample 
quality, buffer condition e.g. pH variation by monitoring the peak positions and linewidths. After 
accomplishing the sequence-specific assignment of the backbone NH peaks in the spectrum, each 
amino acid residue can be monitored during additional titration or interaction experiments.  
1H-15N HSQC is a one-bond heteronuclear correlation experiment. The two frequency coordinates 
are the chemical shifts of a 15N heteronucleus and a proton that are directly scalar coupled through 
one bond. In the protein spectrum, this cross-peak in the two-dimensional HSQC spectrum can be 
assigned as a backbone amide bond, a side-chain NH2 of Asn or Gln residues or a side-chain NH 
group from Trp, His or Arg residues. 
36 
 
The experiments were recorded at a temperature of 20 ̊C by using the “AR_hsqcctetgpsisp_ali” 
pulse sequence on a Bruker Biospin 500MHz/B-SE/TXI NMR spectrometer equipped with a 5mm 
TXI cryogenic probe at the New York Structural Biological Center. The free induction decay (FID) 
was collected using Topspin3.5pl7 software. The raw data were processed by NMRPipe, an NMR 
spectral processing system (Frank Delaglio, National Institutes of Health). The NMRPipe program 
tracked all operations, produced the correct chemical shifts after complicated maneuvers and 
generated an “nv” file. Then the nv file was read and visualized by using NMRViewJ (Bruce A. 
Johnson, One Moon Scientific). Spectral assignment and chemical shift perturbation were 
accomplished and summarized by NMRViewJ. 
Titration is a simple and efficient way to study and localize the interacting structural regions 
involved in protein-ligand and protein-protein interactions. It is actually a series of 1H-15N HSQC 
experiments with a progression of protein-ligand or protein-protein molar ratios. For the AFABP-
OLA and AFABP-LOLA titrations, the experiments started with 200 𝜇M apo-AFABP as a 
reference. Then aliquots of OLA or LOLA were added to obtain AFABP-ligand ratios of 1:0.1, 
1:0.25, 1: 0.5, 1:0.75, 1:1, 1:1.5, 1:2 and 1:3.  
2.4.1. 1H-15N-TROSY-HSQC of 15N-AFABP titrated by unlabeled PPAR𝛾 
In order to identify the interface on the AFABP side, the 15N labeled AFABP was titrated by the 
unlabeled PPAR𝛾 in the methods of 1H-15N-TROSY-HSQC NMR. In the apoAFABP_apoPPAR𝛾 
titration trials, 95 𝜇M AFABP was prepared with gradient concentration of PPAR𝛾. The molar 
ratios were chosen at 1:0.1, 1:0.25, 1:0.5, 1:0.75, 1:1, 1:1.5, 1:2, 1:3, 1:4 and 1:6. The data was 
collected in the 800 MHz magnetic field with 1.7 mm micro cryoprobe in New York Structural 
Biology Center (NYSBC). The data was processed and analyzed by NMRDraw and NMRViewJ 
software respectively. For the OLAAFABP_OLAPPAR𝛾 titration, 95% protein was saturated to 
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holo form in order to prevent the large amount of free ligand appearing in solution and meanwhile 
suppress the apo peak in spectrum, since 5 𝜇M (5% of 95 𝜇M) apo protein is invisible to our 
receiver coil. 
 
2.4.2. Multidimensional NMR Experiments 
In order to identify the residue corresponding to each cross-peak in the 1H-15N HSQC NMR 
spectrum, we employed the 15N TOCSY-HSQC and 15N NOESY-HSQC experiments89. In 15N 
TOCSY-HSQC, an isotropic mixing step transfers magnetization between networks of chemically 
bonded 1H spins. Then the magnetization is transferred to neighboring bonded 15N nuclei and back 
to 1H for detection. This experiment is useful to identify the amino acid residue types. In 15N 
NOESY-HSQC, the magnetization is exchanged between paired hydrogens within ~ 5 Å using the 
nuclear Overhauser effect (NOE). Then the magnetization is transferred to bonded 15N nuclei and 
back to 1H for detection. This latter spectrum can be used to obtain structural information on any 
correlation through a close distance. This is an effective way to confirm the assignment of proteins 
in the current work, since the part of the assignment was previously accomplished relying primarily 
on C𝛼/𝛽 connectivity (CBCA(CO)NH and HNCACB experiments and side-chain 
1H connectivity 
(H(CCO)NH-TOCSY and TOCSY-HSQC)31. The 3D CBCA(CO)NH experiment is specifically 
designed to correlate the 1H and 15N amide resonances of one residue with both 13CA and 13CB 
resonances of its preceding residue via the intervening 13CO spin by means of the 1J(NH), 1J(N,CO), 
1J(CA,CO) and optional 1J(CA,CB) coupling constants. The 3D HNCACB experiment is designed 
to correlate the 1H and 15N amide resonances with those of the intra- and interresidue 13CA 
and 13CB resonances by means of the 1J(NH), 1,2J(N,CA) and optional 1J(CA,CB) coupling 
constants. By combining the information from these two experiments, we can assign the both the 
residue types and position in the polypeptide sequence. 
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The protein samples (apo-AFABP, holo-AFABP, apo-LFABP or holo-LFABP) had a 
concentration as high as 500 𝜇M to conduct the 3D experiments. The FIDs were recorded using 
the same 500 MHz instrument as described above.  
2.5. Mass spectrometry (MS) 
2.5.1. Matrix-Assisted Laser Desorption/Ionization-Time of flight (MALDI-TOF) 
MS is a quite efficient and accurate way to identify the exact protein and ligand components in a 
sample solution according to their masses. Two types of MS were used in this project. One is 
Matrix-Assisted Laser Desorption/Ionization-Time of flight (MALDI-TOF)90. Samples in MALDI 
will be proton charged and pulse laser-ionized into an electric field. Then different molecules will 
be separated on the basis of the mass-to-charge ratio (m/z or m/Q). This is a more accurate way to 
identify the purity of the sample than SDS-PAGE, although the SDS-PAGE method is faster and 
less expensive.  
Electrospray ionization is another widely used MS method91. Unlike MALDI that denatures the 
protein macromolecules, ESI can spray the sample while maintaining their structure. Therefore, it 
is useful to detect the existence of a protein-ligand or protein-protein complex. In this dissertation, 
it has been applied for both protein and lipid identification.  
 All samples were prepared at 25 μM and mixed with 30 mg/mL sinapinic acid (matrix) at a ratio 
of 1:1 (v/v) in a solvent of 50% Acetonitrile (ACN) and 1% Fluoroacetic Acid (F.A.). All 




2.5.2. Electrospray ionization mass spectrometry (ESI-MS) 
Electrospray Ionization Mass Spectrometry (ESI-MS) was performed on a Bruker Maxis II ETD 
instrument (Bruker Biospin, Billerica, MA). Samples were exchanged with 200 mM ammonium 
acetate by using 10 kDa Amicon Ultra-15 filters, then concentrated to 10 𝜇M before injecting 
into the mass spectrometer at 3 𝜇L/min. Typical native ESI-MS runs used a source temperature 
of 150 °C, dry nitrogen gas kept at 4 L/min, and a collision cell voltage optimized to 5 V. 
In order to measure the lipid (OLA) amount in the protein solution, LC-MS was accomplished by 
connecting an HPLC column (Agilent, Poroshell 5um, 30SB-C3, 2.1 x 75mm) ahead of the Bruker 
Maxis II ETD instrument. The samples were prepared by mixing in 68% methanol:isopropanol 
(v/v, 1:1) and 30% aqueous buffer plus 2% formic acid so as to fully unfold the protein and release 
the bound lipids. Then the samples were injected into the HPLC column with a 90% aqueous 
elution buffer and eluted by an ascending gradient methanol buffer. Since the lipids are much 
soluble in methanol compared to aqueous solvent, at some point of the gradient the lipids will be 
eluted from the column and sprayed into the MS channel. The chromatography and MS signals 
were recorded and analyzed by “Data analysis 4.3”. Our target molecular weight is “281” (OLA). 
The peak that contains the 281 molecule can be extracted and integrated to estimate the amount of 
OLA in the injected samples, since the OLA amount is proportional to the “281” area. In order to 
establish the linear equation which is used for the OLA amount estimation, the calibration curve 
of “281” area versus OLA concentration was plotted using OLA standards at concentrations of 
1.37, 6.86 and 13.7 uM dissolved in the same buffer (68% methanol isopropanol (1:1, v/v), 30% 
protein solvent buffer, 2% formic acid).  
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2.6. Fluorescent lipid (DAUDA) competitive titration  
2.6.1. Validation of ligand binding preference between AFABP and PPAR𝛾 
It Is known that the fluorescent lipid analog 11-((5-dansyl)amino)undecanoic acid (DAUDA) can 
alter its emission wavelength as the polarity of its environment changes. For example, the emission 
of the DAUDA in the presence of phosphate aqueous buffer only is ~535 nm; as a lipid-binding 
protein target is added the peak shifts to ~460 nm which (a blue shift), and the exact wavelength 
depends on the hydrophobicity of the specific binding cavity92. Also when the DAUDA binds to 
proteins, the emission signal intensity can largely increase which can be easily detected and 
distinguished from the free DAUDA emission. 
First, 40 𝜇M DAUDA was mixed with 8 𝜇M of each protein, AFABP or PPAR𝛾, respectively. The 
sample was irradiated at 345 nm and the emission of DAUDA when it binds each protein was 
scanned from 400 to 580 nm as a reference.  
Second, 4 𝜇M AFABP and 4 𝜇M PPAR𝛾 were mixed with 40 𝜇M DAUDA. The emission curve 
was observed and averaged in three repeated trials. The ligand (OLA) was added gradually and 
the emission curves were collected as above.  
Each profile was corrected by subtracting the background signal of the DAUDA solution. The 
intensity versus wavelength was plotted by GraphPad Prism 7 software with the help of Dr. 
Francine Katz.  
The 460 nm (PPARγ-DAUDA) and 520 nm (AFABP-DAUDA) wavelengths were used to 
compare the changes in fluorescence intensity as each ligand was added. It was expected that a 




All of the fluorescence assays were measured using a Perkin Elmer Envision 2100 Multi-Label 
Microplate Reader at Columbia University with the help of Dr. Francine Katz.  
2.6.2. Study of protein-ligand binding affinities by fluorescence displacement assays 
2.6.3. Measurement of protein-DAUDA binding affinities by fluorescence assays 
The protein-ligand binding constant (Kd) can also be estimated using a fluorescence displacement 
assay with DAUDA. The protein-ligand binding constant obtained by this method is Ki (equivalent 
to Kd in general), where the ligand is viewed as a competitor of the protein-fluorophore complex 
which emits the measurable signal. In order to calculate each protein-ligand binding Ki, it is 
necessary to measure the protein-DAUDA binding Kd as a constant parameter first. 
Purified apoAFABP or PPARγ was mixed with DAUDA in 50 mM potassium phosphate, 150 mM 
potassium chloride, pH 7.4 at 25 ̊C, and the resulting fluorescence was measured within one minute 
using a SpectraMax M5 instrument (Ex = 345 nm, Em = 500 nm). The protein concentration was 
increased by successive addition of a purified protein solution from 0 to 8 𝜇M. The DAUDA was 
applied by successive addition from 0 to 20 𝜇M. The data were collected and analyzed by Softmax 
software and plotted by GraphPad Prism 7.0. 
2.6.4. Fluorescence displacement assay to determine ligand-PPARγ and ligand-AFABP 
binding 
The purified PPARγ was fixed at 0.5 𝜇M. The DAUDA was gradually titrated from 0 to 8 𝜇M. 
Every ligand (sodium oleate, linoleic acid and sodium linoleate) was added to achieve 
concentrations from 0 to 50 𝜇M. The system was dissolved in 50 mM potassium phosphate, 150 
mM potassium chloride, pH 7.4. The fluorescence was measured at Ex = 345 nm, Em = 480 nm. 
The data were collected and analyzed by Softmax software and plotted by GraphPad Prism 7.0. 
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The purified apoAFABP was fixed at 2.0 𝜇M. The Em = 520 nm. The other parameters were set in 














3. RESULTS AND DISCUSSION 
3.1. Sample preparation of AFABP93 
3.1.1. Expression and purification of AFABP 
The AFABP gene was transformed into BL21-AI cells and induced by 0.2% L-arabinose at 37 ̊C. 
Cells were treated in the same way as described for PPAR𝛾 LBD. The only difference is the 
method of TEV protease incubation. The digested linker can compete for the TEV protease with 
the undigested A-FABP. Thus a 10 kDa Millipore concentrator was employed to remove the linker 
(~5 kDa). An aliquot of the sample from each step was analyzed by SDS-PAGE to check the purity 
(Error! Reference source not found.). According to the SDS-PAGE result, the A-FABP is pure, 
yielding 40 mg per liter of unlabeled culture. 
 
 
1     2      3    4    5    6     7      8      9    10  11  12   13  14 
Figure 11. 4-12% SDS-PAGE gel of PPAR𝛾 LBD expression and purification.  
Gel of the AFABP expression and purification: 1, protein marker ladder; 2, medium culture 
before induction; 3, twenty hours after induction; 4, cell lysate after sonication; 5, insoluble 
phase of the cell lysate; 6, supernatant of the cell lysate; 7, pooled HisTrap elution fractions; 
8, supernatant after adding 13C_OLA solution; 9, pooled GF fractions; 10, after 5 minutes 
incubation with TEV protease; 11, after 1 day incubation with TEV protease; 12, 13, sample 
filtration by 10 kDa cut-off Millipore filters. 14, after HisTrap removing the TEV protease 
and the removed linker 
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3.1.2. Delipidation of AFABP 
Previously, we employed Lipidex-1000 beads to remove the endogenous lipids from AFABP. 
However, even duplicate treatments with the Lipidex-1000 packed column failed to delipidate the 
AFABP completely, as demonstrated by the retention of extra peaks in the HSQC NMR spectrum 
(data not shown). We suppose that the hydrophobicity is not high enough to compete for the 
ligands with AFABP. In this case, we located an alternative Lipidex-5000 product, which is 50% 
substituted with long-chain carbon chains and more hydrophobic. About 25 g of beads were packed 
into an Invitrogen XK-26 column at 37 C̊, through which ~40 mg of protein was eluted. An aliquot 
was concentrated and examined by 1H-15N HSQC to assess the degree of delipidation. 
Unfortunately, the delipidating effect was insufficient; after treatment there was still some portion 
of AFABP remaining in the holo form.  
We suspected that the low efficiency might come from the short retention time. Thus, we let the 
protein incubate with the bulk beads directly and swirled the mixture in a 50 mL Falcon tube at 
37 ̊C for 2 hours. After treatment, the beads were removed by a 0.22 𝜇m Amicon Filter. In order 
to obtain the highest efficiency of delipidation, we repeated the treatment. In the resulting 1H-15N 
HSQC spectra (Figure 12, D and E), we could observe that the peaks were characterized to be in 
the apo form. Remarkably, there were no holo peaks observed even down at the lower contour 
level. More than 95% AFABP is in apo form by calculating the proportion of apo and holo peak 
intensities.Thus nearly all of the AFABP was converted to the apo form after twice swirling 







Figure 12. 1H-15N HSQC spectra of the 15N AFABP delipidation by Lipidex-5000 treatment. 
The peaks used for confirming apo or holo forms are marked by green rectangles. A, the 15N 
AFABP sample obtained after TEV protease cleavage but before delipidation; B, the 
spectrum 15N AFABP after double swirling treatment Lipidex-5000 beads; C, lower contour 
levels of the spectrum in B; D, delipidated 15N AFABP (black) overlaid with holo-OLA-
AFABP2; E, lower contour levels of the spectrum in D.   
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3.1.3. Study of homodimers of AFABP 
3.1.3.1. The dimer can be separated from the monomer by GF 
Although it has been widely assumed that FABPs are present in monomeric form at the near-
physiological concentrations used for thermodynamic and NMR studies of their interactions with 
ligands and other proteins, non-covalently associated dimers were proposed by Gillilan et al 94. 
Such associated species would not be evident in the denaturing SDS-PAGE gels of Error! 
Reference source not found. and could conceivably be missed in the 2D HSQC NMR spectra of 
Figure 12 due to the modest molecular weight of this protein. To establish the oligomeric state of 
the apo-AFABP sample, a series of protein samples at concentrations from ~10 to ~500 𝜇M were 
analyzed by gel filtration size exclusion chromatography89, typically after refrigerated storage for 
up to 25 days. The resulting elution profiles, which are overlaid in Figure 13A, each displayed two 
well-separated peaks from protein species that differed in molecular size, as deduced from their 
respective retention volumes. Reference to calibration standards showed that the leading and 
lagging peaks correspond to approximate molar masses of 32 kDa (an AFABP dimer) and 16 kDa 
(the monomer). Each profile showed the lagging peak to be predominant; integration yielded a 
nearly invariant dimer proportion of 13±0.3% over this 50-fold concentration range. Moreover, 
GF trials with 2:1 holo-AFABP liganded to oleate, linoleate, or troglitazone (a member of the 
thiazolidinediones antidiabetic drug family) revealed monomer percentages: 99±1%, 95±5%, and 
91±1%, respectively, for dilution series from 500 to 10 μM 95. The reason of this invariant dimer 
proportion is not sure. The difference might occur occasionally because later it has been proved 








Figure 13. Elution profiles for murine adipose fatty acid-binding protein obtained from size 
exclusion chromatography (gel filtration with Superdex 75). A: Dilution series (462 μM; 
royal blue to 11.5 μM; navy blue) of twice-delipidated apo-AFABP samples stored for one 
month at 4°C and analyzed in triplicate, showing reproducible dimer percentages within 1% 
for each sample and a nearly invariant dimer percentage (13.3±0.3%) throughout the 
indicated 50-fold concentration range. B: Recovered leading fraction (green) and original 
15.2±5.6 μM apo-protein elution shown in panel A (blue). C: Recovered lagging fraction (red) 
and original 231.0±0.8 μM apo-protein from the elution shown in panel A (blue). Each trace 
in panels B and C represents an average of three GF chromatograms. 
 
The trend in GF-based relative populations reported above would be anomalous if non-covalent 
association of AFABP molecules established a monomer-dimer equilibrium, as proposed in related 
protein samples under different experimental conditions based on crystallographic, fluorescence, 
and small-angle light scattering evidence93-94. In that type of dimer, the predominant monomer 
proportion should indicate weak binding affinity; then as the sample is diluted, the dimer 
proportion should decrease to a vanishingly small value rather than remaining constant. 
Conversely, if the AFABP dimer is linked by one or more covalent bonds, then it is possible to 
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account for the observed constancy of the dimer proportion as a function of overall protein 
concentration.   
In order to test this latter proposal, the leading and lagging fractions from the GF column were 
each recovered and subjected to another round of size exclusion chromatography. In the case of a 
non-covalent interaction, the leading and lagging fractions should each re-establish the identical 
monomer-dimer equilibrium state that would be reflected in the subsequent GF elution profile. 
Otherwise, there should be a greater dimer proportion observed from the recovered leading fraction 
and a lesser proportion from the corresponding lagging fraction, respectively. Figure 13 B and C 
show GF profiles that illustrate the larger relative amount of dimer in the recovered leading fraction 
compared to the recovered lagging fraction. This trend argues strongly for an AFABP dimer that 
is held together (irreversibly) by covalent bond(s). The hypothesis of a leading GF fraction in 




Figure 14. Native ESI-MS verification of the recovered leading fraction (dimer) from the GF 
chromatogram of apo-AFABP (Figure 13B). The 8+ charged peak at m/z 29,748 Da 
corresponds to the monomer of AFABP (14,874 Da); the remaining three peaks are dimeric 
AFABP with various charges ranging from 12+ to 14+. The light blue lines provide a 
reference frame to identify the peak assignment. 
 
3.1.3.2. The AFABP dimer is linked by disulfide bond(s)  
Given the common observation of disulfide bonds in proteins 96 and the presence of two surface-
accessible cysteine residues in AFABP 97, we hypothesized that our dimer is covalently linked in 
this fashion. This supposition was tested by monitoring the protein mass in the presence or absence 
of a 𝛽-mercaptoethanol disulfide bond reductant. The SDS-PAGE gels of Figure 15 showed a 
dimer band that disappeared upon treatment with a 𝛽-mercaptoethanol (BME) reductant. The 
retention of the 29-kDa band in the absence of BME suggests that the dimer is covalently bound 
rather than self-associated; its disappearance in the presence of BME supports identification of the 
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AFABP covalent bond as a disulfide linkage. Interestingly, only monomers were observed from 
the initial GF conducted during purification and in the recovered lagging fraction samples isolated 
directly after GF elution, but the dimer proportions grew to ~13% and ~16%, respectively, during 
refrigerated storage for one month. 
 
Figure 15. Characterization of covalently bound AFABP oligomer by 15% SDS-PAGE. Lane 
1, protein marker ladder; lane 2, AFABP monomer recovered from the lagging fraction in 
GF chromatography; lanes 3 and 4, AFABP dimer from the leading GF fraction, omitting 




3.1.3.3. The AFABP dimer forms through an N-terminal cysteine residue  
Either of the two cysteine residues within the AFABP protein is a candidate for dimer formation 
via a disulfide bond, though the N-terminal Cys-1 is expected to have a somewhat more surface-
accessible location than Cys-117. In order to verify the location, the recovered AFABP monomer 
and dimer fractions were each examined using 2D 1H-15N HSQC NMR.  The overlaid spectra of 
Figure 16 reveal differences in chemical shift for several peaks, i.e., significant perturbations in 
magnetic environment for the backbone amide group in particular molecular regions. Sites for 
which the weighted 1H and 15N perturbations 98 exceeded one standard deviation beyond the mean 
value (Figure 17) were mapped onto the crystal structure of the protein (PDB: 2Q9S)93-94. Figure 
18 shows that the most perturbed region of AFABP is located at the N-terminus, close to the 
location of Cys-1. These NMR results support the formation of a disulfide bond through the 




Figure 16. 500 MHz 1H-15N HSQC NMR99 contour plot  showing overlaid spectra for the 
recovered monomer (blue, 400 𝜇M) and dimer (red, 200 𝜇M) from GF chromatography of 
AFABP protein samples. Chemical shifts are referenced according to the guidelines of 
Wishart et al93, 100.  Highly perturbed residues are labeled in the spectrum; a complete plot 





Figure 17. Composite 1H-15N NMR chemical shift perturbations vs. AFABP residue number, 
comparing a disulfide-linked dimer to a monomer standard.  Values for unassigned residues 
are left blank. The numerical values are calculated as Δ(dimer-monomer) = ([δHN(dimer) – 
δHN(monomer)]2 + {[ δN(dimer) – δN(monomer)] / 6.31}2)½ 93, 98. The orange cut-off lines at 
0.11 ppm, set slightly below the mean ± one standard deviation of perturbations for each pair 
of protein forms, are used to identify backbone sites with structurally significant chemical 
shift changes. Residue numbering for this protein construct is designated as G(-2)-M(-1)-




Figure 18. Mapping of significant chemical shift perturbations on structures depicted with 
PyMOL [www.pymol.org] for the AFABP dimer  with respect to the corresponding protein 
monomer (PDB: 2Q9S)94. Backbone residues highlighted in red exhibit composite 1H-15N 
NMR chemical shift perturbations of at least one standard deviation beyond the mean value 
observed for 131 sites of the polypeptide. The cysteine residues that could form disulfide 
bonds are highlighted in blue. 
 
3.1.3.4. AFABP dimer formation can be blocked by excluding oxygen gas 
Given that disulfide bond formation is an energy-requiring oxidative process, we hypothesized 
that oxygen gas dissolved in the phosphate buffer solution could effect this chemical 
transformation. Formation of inter- or intramolecular S-S bridges under oxidative stress conditions 
has been established, for instance, in a protein kinase and a protein-tyrosine phosphatase, 
respectively 101. To test our proposal, a month-long course of dimer development was monitored 
for freshly purified apo-AFABP samples in a standard oxygen-saturated buffer vs. a buffer infused 
with oxygen-scrubbed nitrogen gas. The samples were collected at 8-10 day intervals and analyzed 
by GF to assess their respective dimer proportions (Figure 19). During the initial week of the time 
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course the dimer population grew commensurately in the two samples.  Subsequently, dimer 
growth progressed linearly in the standard buffer but was essentially halted in the oxygen-free 
buffer medium. After thirty-five days, the comparative dimer proportions were 19% (oxygen-
saturated control) and 5.5% (oxygen-free). (The estimated value after 25 days is 11%, in 
reasonable agreement with the 13% reported in Figure 13.) These results support the premise that 
dissolved oxygen gas is the reactant responsible for formation of the disulfide bond in the AFABP 
dimer. 
 
Figure 19. Proportion of dimers present as a function of time  for 56.3 𝜇M (assuming all 
proteins are monomers) freshly prepared AFABP samples that were stored in buffers 
saturated with oxygen (blue curve) or infused with oxygen-scrubbed nitrogen gas (red curve). 
Percentages were derived from elution profiles of Superdex 75 size exclusion gel filtration 
chromatography analogous to those illustrated in Figure 13. Error bars denote results from 
triplicate GF runs on the same sample. 
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3.2. Sample preparation of LFABPs 
3.2.1. Expression and purification of LFABP   
The LFABP was induced in two different temperatures: 37 ̊C and 18 ̊C. According to Figure 20 
(lanes 3 & 9), the LFABP was successfully expressed and produced at both temperatures. However, 
most of the protein was found in the insoluble form (Figure 20, lanes 5 & 11) at a growth 
temperature of 37 ̊C. Thus the 18 ̊C choice was more suitable for this cell line to generate soluble 
LFABP. This production of insoluble inclusion bodies is a quite common problem for induction 
of proteins at 37 ̊C in the BL21 cell line102. 
1          2           3          4          5            6                                7           8            9          10         11       12 
Figure 20. SDS-PAGE of LFABP expression at 37 ̊C and 18 ̊C. Lanes 1 and 7, protein marker 
ladder; lanes 2-6, samples from 37  ̊C growth; lanes 8-12, samples from 18  ̊C; lane 2, before 
induction at 37  ̊C; lane 3, 5 hours of induction at 37  ̊C; lane 4, cell lysate after sonication; 
lane 5, insoluble fraction after centrifuging the sonicating lysate; lane 6, soluble supernatant 
after centrifuging the sonicating lysate; lane 8, before induction at 18  ̊C; lane 9, 24 hours 
induction at 18 ̊C; lane 10, cell lysate after sonication; lane 11, insoluble fraction after 
centrifuging the cell lysate; lane 12, soluble supernatant after centrifuging the cell lysate. 
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After HisTrap and gel-filtration purification as outlined above, the LFABP with a 6 x histidine tag 
was pure as judged by SDS-PAGE (Figure 21A, lane 2). The procedure of primary expressions 
and purifications the LFABP was accomplished by Dr. Cédric Bernard and Dr. Sayantani Sarkar. 
In order to remove the Histidine tag, a TEV cleavage protocol was carried out at 30 ℃ . 
Unfortunately, the incubation always proceeded incompletely (Figure 21B, lanes 4 and 5). 
Extension of the incubation time did not improve the result (Figure 21B, lanes 7, 8, 10 and 11). 
We suspected that the N-terminal Histidine-tag (linker), which had a molar mass of 3.5 kDa, was 
a reversible competitor of the TEV protease for binding with uncleaved LFABP. As the reaction 
proceeded, more and more of the linker was removed and released, but it could still be recognized 
and bound by TEV protease. That could explain why the initial TEV digestion worked well, but 
as time went on the reaction rate became quite slow. In order to solve this problem, we used a 
Amicon Ultra centrifugal 10 kDa filter. Since our protein, the TEV, and the linker are 15 kDa, 30 
kDa and 3.5 kDa respectively in mass, a 10K filter should allow only the linker to flow through 
while the TEV and our LFABP remained in the inner tube of the filter. By removing the linker in 
real time, the digestion continued to almost 100% completion (Figure 21 C, lane 15). The amount 








Figure 21. SDS-PAGE of LFABP purification. A) LFABP after HisTrap and gel-filtration 
purification. B) LFABP TEV cleavage. Lane 1, protein standards; lanes 2, 4, 7, 10, 0-3 hours 
processing of cleavage with old batch of TEV; lanes 3, 5, 8, 11, 0-3 hours processing of 
cleavage with freshly prepared TEV; lanes 6-9, flow-through of 3K filters. C) LFABP TEV 
cleavage. Lane 1, protein standards; lanes 2, 4, 8, 10, 14, 1-4 hours processing of cleavage 
with old batch of TEV and using 10K filters; lanes 3, 5, 9, 11, 15, 1-4 hours processing of 
cleavage with freshly prepared TEV; lanes 6, 7, 12, 13, flow-through of 10K filters. 
A) B) 
C) 
1     2 
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3.2.2.  Delipidation of LFABP 
Since we have future plans to study the interaction and ligand transfer between LFABP and 
PPAR𝛼 LBD, both apo-LFABP and apo-PPAR𝛼 LBD were required. When pure LFABP and 
PPAR𝛼 LBD are obtained after TEV cleavage, it is expected that endogenous lipids and other 
unknown molecules remain in the binding cavity. Prior publications, including ours and those of 
our collaborators93, 103, used Lipidex-1000 and monitored the removal of 14C-labeled radioactive 
OLA until the counts reached background levels. Radioactive monitoring was also reported for 
delipidation with Hydrophobic Interaction Chromatography (HIC)78; we used 1H-15N HSQC NMR 
as a monitoring method for HIC delipidation of both L-FABP and PPAR𝛼 LBD to avoid the use 
of radioactive isotopes. However, the spectra of holo-OLA-15N-LFABP before and after HIC 
treatment showed only modest differences (blue and green spectra). On the premise that the protein 
might require more incubation time to allow the OLA to be extracted, we decreased the flow rate 
from 1ml/min to 0.1ml/min and allowed both duplicate and overnight incubation (Figure 22, 
orange, magenta) in a sequential fashion. The spectra remained quite similar to those observed 
before HIC. We concluded that fatty-acid (OLA) binds tightly enough within the LFABP cavity 
to preclude competition and ligand extraction by the HIC column.  
We then proceeded with an alternative delipidation route using a Lipidex-1000 column, which 
suffers from high costs and requirements for a stable 37 ℃ working temperature, slower flow rate 
(0.01ml/min), and time-consuming column unpacking and re-packing of the beads before each use. 
The resulting NMR spectra indicated some differences with respect to the initial holo-OLA-
LFABP sample (Figure 23, cyan). For instance, some holo-OLA-L-FABP peaks disappeared 
(Figure 23, blue box) and several new peaks appeared, as expected for apo-LFABP (Figure 23, 
Figure 24, blue box). These changes suggest that our sample is moving towards the apo form, but 
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the delipidation was viewed as incomplete. A second Lipidex treatment produced a very similar 
number and magnitude of peak alterations, i.e., very little further progress toward obtaining the 
protein in apo form. Both spectra from the Lipidex-treated samples displayed broader peaks than 
the holo form (Figure 24, blue circle) and were missing several peaks that had been established 
previously in apo-LFABP (Figure 24, green circle). Based on these observations, we can conclude 
that our protein started to be delipidated but could no longer progress.  
Given the similarity between the current delipidation protocol and our prior successful 
procedures103, we considered the possibility of improper and lengthy storage of the Lipidex beads. 
Re-purchase of the same beads from same vendor, including a check regarding manufacturing 
changes, yielded the same disappointing results (spectra not shown). Attempts were made to 
regenerate the beads with either methanol or petroleum ether to solubilize the highly hydrophobic 
fatty acids using a mobile phase (flowing solvent) that is much more hydrophobic than Lipidex. 
Nevertheless, we were not able to improve the delipidation and reproduce the published spectrum 
obtained by He, et al.28 Ultimately, this delipidation challenge was met by group members May 
Poh Lai and Francine Katz, who built on Cédric Bernard’s work to develop a butanol extraction 
delipidation protocol for LFABP that was validated spectroscopically and by re-binding of the 




Figure 23. 1H-15N HSQC spectrum of holo-OLA-15N-L-FABP (blue) overlaid with one-time 
Lipidex-1000 flow-through (cyan) and two-time Lipidex flow-through (pink).  
Figure 22 1H-15N HSQC spectrum of holo-OLA-15N-LFABP  (blue) overlaid with HIC 
delipidated-LFABP (first flow-through, light green; second flow-through, orange; flow-




Figure 24. 1H-15N HSQC spectrum of apo-15N-LFABP (reference, red) from He et al28 is 
overlaid with one-time holo-OLA-LFABP Lipidex-1000 flow-through (cyan) and two-time 




3.3. Sample preparation of PPAR𝛾 
3.3.1. Molecular cloning of the PPAR𝛾 LBD 
The recombined PPAR𝛾 LBD DNA sequence designed and cloned by Dr. Cédric Bernard was 
validated by GENEWIZ sequencing. The confirmed plasmid (pET-57-DEST) carrying the PPAR𝛾 
LBD DNA was successfully transformed into two cell lines, BL21-AI and BL21-pLysS, 
distinguished using LB agar plates with ampicillin antibiotics.  
3.3.2. Expression and purification of the PPAR𝛾 LBD 
The BL21-AI cell line expressed the protein well when it was cultured in LB medium. About 200 
mg of recombined NusA- PPAR𝛾 LBD was produced from 1 L of culture, yielding about 100 mg 
of pure PPAR𝛾 LBD protein after removal of the NusA and histidine-tag. However, this cell line 
did not perform well during growth in minimal medium, which was required, for instance, to label 
the protein with 15N isotopes for NMR studies. In comparison, the BL21-pLysS cell line generated 
more protein when it was incubated in minimal medium. In Figure 25 lane 10, the PPAR𝛾 was 











The quality of the PPAR𝛾 LBD was validated by MALDI-TOF as shown in Figure 26. The 
predominant peak indicates that the PPAR𝛾 LBD was well purified and yield a measured 
molecular weight of the PPAR𝛾 LBD of 31062.178 Da compared to the calculated 31052.1 Da by 
ProtParam Expasy. In sum, the PPAR𝛾 LBD can be successfully expressed and purified by 
following the protocols described in an ealier section to yield about 100 mg of non-delipidated 
PPAR𝛾 LBD from 1 L of LB medium culture. Since the PPAR𝛾 LBD always binds endogenous 
lipid when it is produced in the BL21 cell line, it is critical to remove those lipids before we study 
its ligand binding. 
Figure 25 SDS-PAGE Gel of the PPAR𝛾 LBD expression and purification: Lane 1, protein 
marker ladder; 2, medium culture before induction; 3, four hours after induction; 4, cell 
lysate after sonication; 5, insoluble phase of the cell lysate; 6, supernatant of the cell lysate; 
7, after 5 minutes TEV protease incubation; 8, after 1 day TEV protease incubation; 9, 
after 3 days TEV protease incubation; 10, pure PPAR𝛾 LBD after His-tag removal. 





Figure 26 MALDI-TOF of the PPAR𝛾 LBD after purification. The predominant peak mass-
to-charge ratio (m/z) 31062.178 indicates the measuring molecular weight of the measuring 
object (PPAR𝛾 LBD). The minor peak m/z 15529.760 indicates the half molecular weight of 
the measuring object. 
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3.3.3. Delipidation of the PPAR𝛾 LBD 
The purified PPAR𝛾 was incubated with apoAFABP which had been fully delipidated by Lipidex-
5000 and then separated in a Supedex 75 gel-filtration column. The delipidated samples were 
denatured and launched to the ESI-MS to measure the released amount of OLA and thus estimate 
the proportion of PPAR𝛾 in the apo form. The results are shown in Figure 27.  
According to Figure 27, 97% of PPAR 𝛾 is in apo form. This indicates that the OLA can transfer 
from PPAR𝛾 to AFABP by incubating and separating using a in the methods of gel filtration 
column. However, the biological expectation is that the ligand transfers from AFABP to PPARγ. 
More experiments and results will be discussed in later section 3.6.4. In addition, negative-mode 
ESI-MS is shown be an effective way to measure the OLA amount. 
Since the ligand removal is based on GF chromatography, each cycle of purification result in loss 






















OLA amount in PPARγ and AFABP samples
Figure 27 Histogram of OLA amount from each 3𝜇M protein sample measured by ESI-MS. 
PPAR𝛾_non, the PPAR𝛾 without any delipidating treatment; PPAR_2nd, the PPAR 𝛾 after 
twice incubated and separated with apoAFABP; PPAR_3rd, the PPARg after three times 
incubated and separated with apoAFABP; AFABP_1st, the AFABP incubated and 
separated from PPAR_non; AFABP_2nd, the AFABP incubated and separated from 
PPAR_1st, AFABP_3rd, the AFABP incubated and separated from PPAR_2nd. 
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3.4. Sample preparation of PPAR𝛼 
3.4.1. Attempted expression and purification of the PPAR𝛼 LBD 
The PPAR𝛼 LBD cDNA sequence was validated by GENEWIZ sequencing. The confirmed 
plasmid (pDEST17) carrying the PPAR𝛼 LBD DNA was successfully transformed into BL21-AI 
cells. The protein was quite well induced. But all of the material stayed in the insoluble phase 
(Figure 28, lane 6). The conditions were optimized at different temperatures (18 ̊C or 37 ̊C) and 
media. None of these modifications solved the protein solubility problem. To solve this problem, 
we connected the PPAR𝛼 LBD to a fusion protein which is highly soluble to force our protein to 
fold and remain soluble. 
Figure 28 SDS-PAGE of PPAR𝛼 LBD expression in LB medium at 18 ̊C. Lane 1, protein 
marker ladder; lane 2, non-induced culture aliquot; lane 3, 2 hours induced culture aliquot; 
lane 4, 20 hours induced culture aliquot; lane 5, the cell lysate after 20 hours induction; lane 
6, the insoluble fraction after centrifugation of cell lysate; lane 7, the supernatant after 
centrifugation of cell lysate. 
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3.4.2. Molecular cloning of the NusA_PPAR LBD 
The recombined NusA_PPAR𝛼 LBD DNA sequence was validated by GENEWIZ sequencing. 
The confirmed plasmid (pET-57-DEST) carrying the PPAR𝛼 LBD DNA was successfully 
transformed into two cell-lines, BL21-AI and BL21-pLysS, distinguished by LB agar plates with 
ampicillin antibiotics. 
3.4.3. Expression and purification of the NusA_PPAR𝛼 LBD  
The NusA_PPAR𝛼 LBD was successfully expressed with the addition of 1 mM OLA in LB 
medium by BL21-AI cell line. The OLA is intended to stabilize the structure of NusA_PPAR𝛼 
LBD and strengthen the binding to the HisTrap column. As a result, the NusA_PPAR𝛼 LBD was 
overexpressed and purified in an approximate amount of 200 mg per 1 L of LB culture. 
 
Figure 29 SDS-PAGE of the PPAR𝛼 LBD samples during each step of expression and 
purification. 1, protein marker ladder; 2, cell lysate after sonication; 3, insoluble fraction 
after centrifugation; 4 soluble supernatant after centrifugation; 5-10, the unbound fractions 
during the HisTrap; 11-15, the elution fractions of the HisTrap with a gradient of imidazole. 




The NusA_PPAR𝛼 LBD was well expressed and purified, but when it was incubated with TEV 
protease to remove the histidine-tag, 99% of the protein irreversibly precipitated. The TEV co-
precipitated as well, which might cause it to form an insoluble complex with PPAR𝛼 LBD. 
Alternatively being explored in our laboratory include insertion of a Thrombin cleavage site, or 
re-designed by connecting the protein to His-tag at the C-terminal and scanning for the best 
expressing cell lines. 
3.5. Assignment of AFABP HSQC spectrum 
3.5.1. 3D TOCSY-HSQC and NOESY-HSQC 
Previously, the AFABP HSQC spectrum was been partially assigned by Dr. Samar Rizk, but since 
the AFABP was discovered to not be fully delipidated, the assigned spectrum was actually a 
mixture of both apo and holo forms. Building on the previous assignment, the 3D TOCSY-HSQC 
and HOESY-HSQC NMR data were recorded and analyzed in NMRViewJ (Figure 30). 143 and 
126 peaks were observed in apo-AFABP and holo-linoleate-AFABP spectra and 117 (90%) and 







Figure 30 Part of the 3D spectra used in protein assignment. NOESY-HSQC (white strip) 
and TOCSY-HSQC (light green); Intra-molecular interaction (blue line); sequential 
interaction (orange line). 




3.6. Interaction between AFABP and PPAR𝛾 
3.6.1. Fluorescence titration to compare protein affinities for OLA  
In section 3.3.3, the PPAR𝛾 was shown to be successfully delipidated by incubating with the 
apoAFABP. This result indicates that in vitro the ligand (OLA) prefers to bind AFABP rather than 
PPAR𝛾, which is opposite to the biological direction of ligand transfer from AFABP to PPAR𝛾. 
In order to further confirm this suspicion, a fluorescence titration was performed. Meanwhile, the 
ligand binding Kd of PPAR𝛾 should be available from the competitive titration. 
The fluorophore used was 11-((5-dansyl)amino)undecanoic acid (DAUDA), for which the 
emission peak will be altered in different environments. In Figure 30A, the DAUDA-PPAR𝛾 and 
DAUDA-AFABP emission peaks occur at 480 and 520 nm, respectively. Moreover, the PPARγ-
bound DAUDA emission intensity was approximately 3-fold higher than the AFABP-bound 
DAUDA. This could be a sign that the PPARγ can bind a maximum of more than one ligand, a 
hypothesis that needs further study. It is known independently that a DAUDA blue-shift reflects 
the local hydrophobicity. So according to this result, we conclude that the PPARγ binding cavity 
is more hydrophobic than AFABP. Since the DAUDA can emit at different wavelengths, it is also 
possible to deduce which protein will bind the ligand preferentially based on the shift of the 
emission peak. 
The apoAFABP and apoPPAR𝛾 were mixed at a molar ratio 1:1 and pre-equilibrated with an 
excess of DAUDA. In this case, both AFABP and PPAR𝛾 bind DAUDA and emit (Figure 31B red 
curve). As the ligand (OLA) was added, the peak intensity decreased and exhibited a blue shift as 
expected. The reason the peak decreased was because the DAUDA was replaced by the OLA. The 
blue shift indicates that the DAUDA-AFABP lost the signal more readily. In another words, the 
OLA binds AFABP preferentially to PPAR𝛾. 
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This result can be interpreted in another way. Instead of comparing the entire scan of wavelengths, 
it was informative to examine the specific wavelengths of 460 nm and 520 nm.  The intensities at 
these two extremes were compared at each titration increment (Figure 31C and 30D). Evidently, 
the intensity at 520 nm dropped more readily than the one at 460 nm. Since 520 nm is dominated 




Figure 31 Fluorescence assay of oleate titration of a AFABP-PPAR𝛾-DAUDA mixture. A: 
red, 8 𝜇M of apoAFABP mixed with 40 𝜇M DAUDA; blue, 8 𝜇M of apoPPAR𝛾 mixed with 
40 𝜇M DAUDA; B: titration curves as OLA is increased (from red to blue); C: intensity bar 










































3.6.2. Fluorescence titration to obtain the relative protein-ligand binding affinities  
In order to obtain the relative binding affinities of the protein-ligand complexes based on the 
protein-DAUDA experiments, the ligand-bound percentages were calculated by using the formula 
shown below. The percentage values are plotted on decimal and logarithmic scales shown in Figure 
32 A2&B2 and A3&B3.  
Ligand bound % = 
(𝑠𝑙𝑜𝑡 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦−𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑)
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑
 × 100 % 
By fitting each curve from Figure 32 A2&B2 to the Michaelis-Menten equation, the IC50 
52 is 
obtained and shown in Figure 33. It is observed that there is a trend that both AFABP and PPARγ 
binds the OLA tighter than LOLA. These fluorescence results are promising but preliminary in 






Figure 32 Protein-ligand titration fitting to the Michaelis-Menten equation.A1: 2 𝜇M 
apoAFABP titrated with OLA (red) or LOLA (green) in the presence of 4𝜇M DAUDA. B1: 
0.5 𝜇M PPARγ titrated with OLA (red) or LOLA (green) in the presence of 4𝜇M DAUDA. 
A2 & B2: conversion of A1 & B1 fluorescence to ligand-bound percentage by being 
subtracted and dividing by the initial fluorescent signal without any ligand. A3 & B3: 
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Figure 33 IC50 values by fitting the curves from Figure 32 A2 and B2 to the Mechaelis-Menten 
equation.A: IC50 values of AFABP bound LOLA (dark green) or OLA (dark red). A: IC50 
values of PPARγ bound LOLA (dark green) or OLA (dark red). 
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3.6.3. 1H-15N-TROSY-HSQC of 15N-AFABP titrated with unlabeled PPAR𝛾 to define 
binding interface 
3.6.4. NMR chemical shift perturbation due to 15N AFABPs - apoPPAR𝛾 interaction 
Results from titration of apoAFABP titrated by apoPPARγ are shown in Figure 34A. According 
to the spectra, most of the peak position were invariant; exceptions included the peaks in the 
zoomed region, which migrated as the apoPPARγ was added. It is clear that resonances are in the 
fast exchange regime which can be identified by progressive chemical shift changes of an averaged 
peak rather than relative intensity changes of two peaks. Fast exchange usually indicates that the 
binding between these two apo proteins is weak. The titration of apoPPARγ and holo-OLA-
AFABP was studied as well (Figure 34B). The chemical exchange rate remained fast, similarly to 
the apo_apo titration. The chemical shift perturbation of each residue was calculated as shown 
below. (The spectrum of the holo-linoleate-AFABP_apo-PPARγ titration was not shown but was 
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Figure 34 1H-15N TROSY-HSQC NMR of AFABP titrated by PPARγ. A: overlay of spectra of 
apo15N AFABP titrated by 1-6 fold molar ratio of apoPPARγ; B: overlay of spectra from 
apo15N AFABP titrated by 1-6 fold molar ratio of holo-oleate-PPARγ; C: overlay of spectra 
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According to the Figure 35, most of the perturbed regions for each protein-protein pair span 
residues 29-35, which define the helical structure of the AFABP portal. By mapping onto the 
crystal structure (Figure 36), we observe that the most perturbed residues belong to the portal area. 
There are two particular residues, Asp-17 and Phe-57, which are perturbed significantly in 
spectrum A (apo_apo titration) but disappear in spectrum B (holo_apo titration). The 
disappearance indicates that these specific resonances are in intermediate exchange on the NMR 
timescale (kex ~ 𝛥ω). Thus it is impossible to track the perturbations of these two residues which 
are substantially perturbed in the apo_apo titration. It is not certain whether these peaks will 
reappear in the NMR spectrum, since the titration has been not fully saturated. This non-global 
line broadening effect could indicate large changes in chemical (magnetic) environment at these 
sites, i.e., large 𝛥ω which becomes comparable to kex.  
There are two residues (Val-23, Asp-76) which are perturbed in the apo_apo titration but less 
perturbed in the holo_apo titration. They are mapped to crystal structures in Figure 36. The holo-
OLA-AFABP is colored in green with the OLA ligand shown. The apo-AFABP is colored in red. 
These two residues are at the portal areas as well. 
Finally, there are two residues (Lys-100, Arg-106) which are perturbed in the apo_apo titration 
but more impacted in the holo_apo titration. They are mapped to the crystal structure in both Figure 
36 and Figure 37. It is gratifying to observe that Arg-106, which is critical to ligand binding,104 
has been perturbed during the holo_apo but not the apo_apo titration. It is not clear that whether 
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this interaction is attributable to ligand binding. Future studies could attempt to untangle the 
protein-ligand binding and protein-protein interactions. 
As the titration proceeds, the various peak intensities decrease in both apo_apo and holo_apo 
titrations as shown in Figure 38. This is a good sign that PPARγ binds the AFABP. This global 
broadening effect of the NMR signals is due to the addition of unlabeled PPARγ which binds the 
labeled AFABP and therefore leads to a slower tumbling rate of the complex. 
It is also of interest to note that in the apoAFABP_apoPPARγ titration, residues T29-M35 of the 
portal area do not decrease in intensity as much as the average for the entire polypeptide. 
Comparatively, for the other two titrations, the residues in the portal area decrease more 
significantly than the average. Qualitatively, the least decreasing peaks tend to be located in the 
unstructured turns connecting the 𝛽-strands (Figure 39). Even though the PPARγ binding leads to 
a slow tumbling rate and broadening of the signals in the labeled AFABP protein, exceptions could 
occur at the termini or other highly mobile regions, for example the free coil region105. In order to 
draw more definitive conclusions, the spin relaxation behavior of each residue must be monitored 


































































































































































































































































































































Figure 36 Structural mapping of the perturbed areas. The perturbation level is indicated by 
the gradient of colors. A & B: overlay of secondary structure and surface of apoAFABP 
perturbed by apoPPARγ (1LIB); C & D: overlay of secondary structure and surface of holo-
OLA-AFABP perturbed by apoPPARγ (1LIB). The perturbed areas are colored by red in A 
& B and blue in C & D titrations; oleate ligand is colored in magenta. E & F, overlay of 










































Figure 37 Mapping the structure of the different perturbed areas to compare the apo-





Figure 38 Changes of peak intensity in AFABP_PPARγ titrations. Blue bar, the 
apoAFABP_apoPPARγ peak intensity subtracted from the corresponding apoAFABP peak 
intensities; Red bar, the holo-oleate-AFABP_apoPPARγ peak intensity subtracted from the 
holo-oleate-AFABP peak intensity; Green bar, the holo-linoleate-AFABP_apoPPARγ peak 








Figure 39 Qualitative structural mapping of the intensity-decreasing areas. Regions of 
modest decrease in peak intensity are colored in gradient red; the areas where the peak 
intensity decrease are colored in gradient blue; the unassigned residues are colored in gray. . 
A: apo-AFABP (1LIB); B: holo-oleate-AFABP (1LID); C: holo-linoleate-AFABP (2Q9S). 
Highly decrease 
Slightly decrease 
A B C 
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3.6.5. Dissociation constants Kd for 15N AFABP - apoPPAR𝛾 interaction 
Since the formation of the protein-protein complex is accompanied by proportional changes in the 
chemical shift, it is possible to estimate the protein-protein dissociation constant (Kd) from the 
perturbed peaks. Since the resonances are in the fast exchange regime, it is possible to estimate the 
Kd from the chemical shift changes of the perturbed residues. The calculated perturbations are 
plotted in Figure 40A-C and fitted to the Michaelis-Menten equation with R2 > 0.9 (R2 indicates 
how the data points fit the curves.). According to the Figure 40A-C, all of the data points fit the 
curve well. All of the curves generate their own Kd and are averaged to obtain the Kd of the protein-
protein complex shown in Figure 40D.  
The derived Kd values are rather broadly distributed for different residues. For example, in the 
apoAFABP_apoPPAR𝛾 titration, the Kd ranges from 200 to 1200 𝜇M. Most of the data points fall 
in the range 250-750 𝜇M. There are two outliers: 993 and 1116 𝜇M corresponding to G34 and V30, 
which are both in the portal area perturbed when apoPPAR𝛾 is titrated. In the holo-OLA-
AFABP_apoPPAR𝛾 titration, the Kd mainly ranges from 100 𝜇M to 1 mM, with one upper outlier 
at 1736 𝜇M corresponding (V30) and three lower outliers at 100, 116 and 112 𝜇M (V23, V32 and 
G34). In the holo-LOLA-AFABP_apoPPAR𝛾 titration, the Kd mainly ranges from 250 to 1250 
𝜇M, with two upper outliers at 1833 and 1454 𝜇M (V32 and A33). It is notable that all of these 
outliers pertain to residues in the most perturbed portal area of the AFABP protein.  
The averaged Kds are all in about half millimolar range, indicating that the protein-protein 
interactions are quite weak. The differences among these three averaged Kd are not so significant 
given the large variance for each titration. Although the average Kd is quite high, some specific 
residues V23, V32 and G34 yield small Kd values in the holo-OLA-AFABP_apoPPAR𝛾 titration. 
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Figure 40 Dissociation constant (Kd) of AFABP_apoPPARγ interactions. A: residue chemical 
shift perturbation in apoAFABP_apoPPARγ titration. B: residue chemical shift 
perturbation in holo-OLA-AFABP_apoPPARγ titration. C: residue chemical shift 
perturbation in holo-LOLA-AFABP_apoPPARγ titration. D: layout of Kd estimated by 
fitting the residue perturbation to the Michaelis-Menten equation. E: comparison among 
three individual protein-protein complexes of Kd estimated from V23 (blue bar), V32 (red 
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3.6.6. Ligand transfer between the AFABP and PPARγ 
In section 3.3.3 we demonstrated that most PPARγ-bound oleate (>97%) can transfer from holo-
oleate-PPARγ to apo-AFABP by simply mixing and separating by three successive GF column 
elutions. This results indicates that oleate binds to AFABP more tightly than PPARγ under our 
experimental conditions, although it is opposite to the biological direction. However, during the 
holo-AFABP_apo-PPARγ titrations it was noticed that as the apo-PPARγ was added, some apo-
AFABP peaks appeared (Figure 34). The holo- and apo-proportion could be calculated based on 
their peak intensities, since the ligand binding is in the slow exchange rate. The results are shown 
in Figure 41. According to the histogram, when holo-AFABP was mixed with apo-PPARγ at molar 
ratio 1:1, about 3.9% or 9.1% AFABP-bound ligand (linoleate or oleate) transferred to PPARγ. As 
the molar ratio reached 1:4, about 10.1% or 15.7% AFABP-bound ligand (linoleate or oleate) 
transferred to PPARγ. Although it has been reported that the AFABP level in healthy men/women 
ranges 0.64~1.36 𝜇M / 0.84~1.87 𝜇M106, and 0.9~1.63 𝜇M / 1.27~1.93 𝜇M in Type 2 diabetic 
groups, the corresponding PPARγ has not been reported yet.  
Based on the experiments of PPARγ delipidation and AFABP_PPARγ titrations, we find that the 
AFABP binds the ligands (oleate and linoleate) much tighter than does PPARγ. In another words, 
most of the ligand would bind AFABP first, which is opposite to the biological expectation. 
Nonetheless we also observed that about 3.9-9.1% (3.7-8.6 𝜇M) ligand was able to transfer from 
AFABP (95 𝜇M) to PPARγ (95 𝜇M). This finding suggests that a low level of bound ligand could 
be present and sufficient to activate PPARγ function in gene transcription. In fact, it has been 
reported that the PPARγ transactivation EC50 values are at about 0.01-1.0 𝜇M range,107 suggesting 
that PPARγ transactivation does not require a large amount of ligand to be transferred. In last 
paragraph, it is mentioned that in serum, the AFABP concentration is about ~1 𝜇M. It is not known 
88 
 
that the AFABP concentration in nucleus. Assuming that the AFABP concentration is similar and 
10% is transferred, which is about 0.1 𝜇M, then the ligand will fall into the PPARγ transactivation 
EC50 (0.01-1.0 𝜇M) range which is enough for the PPARγ to initiate its biological function. 
Interestingly, as discussed above, the most perturbed area is located within the portal region which 
also includes the NLS sequence. According to prior reports, there is an NLS sequence existing in 
a 3-D fold mapping to the helix-loop-helix region, which is part of the AFABP portal area. The 
sidechains of K21, R30 and R31 form a functional NLS by shifting their orientation to bind 
different ligands25. The non-activating ligands protrude from the portal and prevent the helical cap 
closure, while activating ligands favor an alternative homodimer to promote the exposure of the 
NLS and facilitate transfer of AFABP to the nucleus. This consideration can also explain how the 
PPARγ obtains the activating ligand (LOLA) even though OLA has greater a greater binding 
preference. Since the non-activating ligands will be blocked by the nuclear membrane, the 
activating ligands will become predominant in the nucleus.  
In this project, only oleate and linoleate have been studied. Other ligands (neutral fatty acids or 
synthetic agonists such as Rosiglitazone, thiazolidinediones and Troglitazone) could also be of 
interest, because PPARγ might specifically bind such ligands much more tightly.  
AFABP is a critical lipid carrier that delivers lipids to many proteins in various organelles. It has 
been well established that AFABP associates with Hormone-sensitive Lipase (HSL)108. This 
research found that association to the HSL requires a bound ligand and that the interface is located 
at helix αI, which is part of the portal region. The AFABP delivers the ligand to the activated and 
phosphorylated HSL to inhibit its function to facilitate a feedback inhibition. Thus, study of the 
interaction between AFABP and HSL could inform investigation of the interaction between 







Figure 41 Bars plot showing estimation of the transferred ligand proportion by measuring the 
remaining holo-AFABP and apo-AFABP proportions. The mean values were calculated by 
averaging peak intensities of 7 residues (N=7). Left, remaining holo-AFABP peak intensity 
proportions at each titrating increment. Right, the newly appeared apo-AFABP peak intensity 
proportions at each titrating increment. Blue bars, titration of holo-oleate-AFABP by apo-





In this project, the interaction sites of AFABP with PPARγ have been studied primarily by NMR 
titration in the presence of different ligands. The most perturbed area is located in the portal region. 
This could indicate that AFABP transfers the ligand to PPARγ through interactions of that region. 
The corresponding PPARγ interaction sites remain undetermined, requiring future assignment of  
the 15N PPARγ amide NH resonances and titration by unlabeled AFABP.  
By calculating the chemical shift perturbation, Kd for the protein-protein complex was estimated. 
The binding interaction is weak (average Kd ~500 𝜇M). Several residues e.g. V23, V32 and G34 
behaved anomalously. For instance, in the holo-OLA-AFABP_apoPPARγ titration, the average 
Kd is 641 𝜇M. The Kds estimated by V23, V32 and G34 are about ~100 𝜇M. It is of interest to 
discover that these residues are mostly perturbed and located at the portal area of the AFABP. This 
might be a sign that these residues are critical for the protein-protein interaction. In order to obtain 
more definitive information, a chemical shift perturbation study of the PPARγ interaction site and 
a possible NOE determination of spatial proximities would be useful.  
It was surprising to discover that the oleate ligand binds the AFABP more tightly than PPARγ, 
since the physiological expectation is ligand transfer directly from AFABP to PPARγ in the 
nucleus. The previous delipidation result for PPARγ proves that AFABP binds the OLA more 
tightly than PPARγ. The NMR titration confirms this result. Although the fluorescence assay has 
not yet provided a specific protein-ligand binding constant, it is clear that the OLA preferentially 
binds AFABP when PPARγ is also present. 
Although OLA preferentially binds the AFABP, our evidence shows that the ligand can transfer 
from holo-AFABP to the apoPPARγ site (10% when holo-AFABP: apoPPARγ = 1) in micromolar 
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level. According to previous studies, ligand present in the nanonolar range can initiate the function 
of the PPARγ. Thus a possible model suggests that in the nucleus, most of the PPARγ stays in the 
apo form; once the AFABP-bound ligand enters into the nucleus, a portion of the ligand transfers 
to the PPARγ. The total amount of holo-PPARγ is evidently large enough to initiate the regulating 
function of the related gene transcription. Validation of this proposal will require more 
experiments and supporting results. 
The differential impact on protein-protein interaction from various ligands has been primarily 
studied by comparing the PPARγ-induced chemical shift perturbation without ligands and in the 
presence of OLA-bound and LOLA-bound AFABP. Overall, the perturbed areas are all at the 
portal region. Nonetheless, several residues exhibit variable perturbations depending on titration. 
It is inconclusive that whether the interaction is ligand independent, but there are several important 
residues e.g. Arg-106 which stabilizes the OLA binding is significantly perturbed in the holo-
OLA-AFABP_apoPPARγ titration rather than the other two titrations. In future more ligands are 
should be incorporated in the protein-protein titration in order to obtain comprehensive knowledge 
on this interaction. 
In this project, the protocols for PPARγ preparation and delipidiation have been improved. 
However, these protocols were not successful for PPAR𝛼 preparation, although they share similar 
secondary structure and biological function. The main problem has been the precipitation of 
PPAR𝛼 after tag removal. The PPAR𝛼 is not quite stable and soluble without the tag and fusion 
protein. Different cell lines and tags are being tried by Stark Lab members. The delipidation of 
LFABP had not been solved when this thesis was written, but Stark Lab members are now able to 
delipidate the protein with the help of 1-butanol. Finally, difficulties were encountered in digestion 
of the TEV protease engineered between our target and fusion protein during FABP purification. 
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Evidently it is realized that the removed linker (histidine tag and NusA fusion protein) still 
competes protease with the uncleaved proteins. By using a 10 kDa Amicon filter, it was possible 
to remove the histidine tag and NusA fusion protein linker immediately to avoid competition with 
the protease for the uncleaved protein. Together, these technical advances offer an encouraging 
prospectus for broader investigations of FABP-PPAR interactions at the molecular level and hope 
for better understanding of metabolic signaling in mammalian cells. 
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